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Dabigatran etexilate is a direct thrombin inhibitor that has become widely used in New 
Zealand. It has been available and fully subsidised in New Zealand since July 2011. Of 
patients who receive oral anticoagulation, 51% are now being treated with dabigatran. 
Although prescribing trends can be followed for dabigatran etexilate their relationship to 
outcomes is unknown. However, current prescribing trends for dabigatran etexilate, in 
relation to outcomes, are largely unknown for New Zealand patients. It is also 
recommended that patients taking dabigatran etexilate have at least annual renal function 
monitoring. Little is known about the current level of monitoring in New Zealand and 
which method of estimating renal function is the most appropriate. Finally, there is 
limited information in real-world patients relating to dabigatran etexilate exposure and 
response and the possible role of therapeutic monitoring in the future. 
Aims 
The aims of this research were: 
1. to describe current use, effectiveness and safety of treatment with dabigatran 
etexilate in the New Zealand population; 
2. to investigate the differences between different estimators of renal function and 
the risk of adverse outcomes for patients with atrial fibrillation when these 
different estimators are used for dose selection of dosing dabigatran etexilate; 
3. to investigate the relationship between dabigatran etexilate exposure and adverse 
response in real-world patients; 
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4. to investigate if clinically appropriate renal function testing recommendations 
were being undertaken in New Zealand primary care for atrial fibrillation patients 
prescribed dabigatran etexilate. 
Methods 
This series of retrospective cohort studies used administrative health data and patient 
records from New Zealand for patients dispensed dabigatran etexilate between 1 July 
2011 and 31 December 2015. Statistical analyses were performed using Stata/IC 
(Version 14.2, StataCorpLP, TX, USA). 
Adverse event (haemorrhage) and treatment failure (systemic embolism (SE) or 
cerebrovascular accident (CVA)) data were extracted and linked to patient specific 
demographic data. Baseline patient characteristics were analysed with descriptive 
statistics to examine trends in dabigatran etexilate prescribing. Raw and adjusted hazard 
ratios including covariates were derived using Cox proportional hazard models. 
Renal function was estimated using Cockcroft-Gault, chronic kidney disease 
epidemiology initiative equation (CKD-EPI) and CKD-EPI adjusted for BSA (CKD-EPI-
BSA). Analysis of variance (ANOVA) and the Wilcoxon signed-ranks test were used to 
compare the difference in renal clearance in relation to age. Discordance rates and 
w ere used as measures of agreement 
between the equations. Outcomes of CVA, SE and haemorrhage were extracted and 
hazard ratios (HR) were derived from Cox proportional hazard models. 
Simulated pharmacokinetic parameters were derived using a published population 
pharmacokinetic model of dabigatran etexilate. Area under the curve calculated for a 24-
hour period at steady state (AUCss), the exposure parameter, was derived using these 
simulations and the dosing data and the exposure-response relationship were 
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investigated. The risk of adverse outcomes at AUCss quartiles was compared using 
Poisson regression and expressed using incidence rate ratios (IRR) (95% CI) adjusted for 
known potential confounders. 
The proportion of patients who had serum creatinine measurements at close proximity to 
treatment initiation and 12 months post were assessed with 95% confidence intervals 
-rank tests for univariate analysis (gender, 
age, ethnicity and deprivation) effects on serum creatinine testing at dabigatran etexilate 
treatment initiation and 12 months post were performed. 
Results 
In total, 52413 patients were dispensed dabigatran etexilate in New Zealand during the 
study time frame. 
1. Multivariate analysis indicated the risk of haemorrhagic events was significantly 
increased by ethnicities of 2.86)) and Pacific 
Peoples (HR; 95%CI: 2.20 (1.49 3.24)), age greater than 80 years (HR; 95%CI: 
1.25 (1.08 1.43)) and more deprived quintile ratings of Q4 (HR; 95%CI: 1.24 
(1.08 1.43)) and Q5 (HR; 95%CI: 1.30 (1.12 1.50)). There was an increased risk 
of thromboembolism and cerebrovascular accident for those greater than 80 years 
of age (HR; 95%CI: 1.79 (1.49 2.15)). 
2. When investigating the effects of different renal function estimators there were 
2425 patients identified in the related datasets. Of these there were 
hospitalisations for 138 (5.7%) haemorrhagic events, 45 (1.9%) CVA/SE and 33 
(1.4%) unspecified CVA. The level of agreement between Cockcroft-Gault with 
CKD-EPI and CKD-EPI-BSA yielded a weighted Kappa statistic of 0.47 and 
0.71, respectively. The hazard ratio for a haemorrhagic event was 2.32 (95%CI, 
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1.22-4.42; p=0.01) when a high dose was given compared to normal dose, based 
on Cockcroft-Gault. 
3. For NVAF patients there was a decreased risk of haemorrhage (0.51, 0.32 0.79) 
when dabigatran AUCss was in the second quartile range of 1.70 1.96 mg*h/L 
and thromboembolism/CVA (0.34, 0.16 0.76) when AUCss was in the third 
quartile range of 1.97 2.26 mg*h/L. An increased risk of haemorrhage (1.68, 
1.18 2.38) was observed when AUCss was in the fourth quartile range of 2.27
12.76 mg*h/L. 
4. There were also 1948 dabigatran etexilate patients identified with available 
primary care health data to investigate compliance to renal function monitoring. 
A total of 1,752 (89.9% [95%CI; 88.5-91.2]) patients had a renal function test at 
dabigatran etexilate initiation. There were 929 (72.8% [95%CI; 70.2-75.2]) 
patients who received one or more years supply of dabigatran and of these 207 
(22.3% [95%CI; 19.6.6-25.1]) had a serum creatinine test one year after initiation. 
Demographic univariate analysis yielded insignificant log-rank tests for 
association with having serum creatinine measurements except for Pacific 
Peoples (p = 0.0230). 
Conclusions 
Demographic factors are associated with adverse outcomes in patients treated with 
dabigatran etexilate. Patients prescribed dabigatran etexilate 
Peoples ethnicity are at greater risk of harm compared with other ethnicities. 
Improvement of outcomes might be achieved by increased vigilance of clinical 
monitoring especially in the the elderly and those 
who are more deprived. 
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Both CKD-EPI and CKD-EPI-BSA equations significantly overestimated renal function 
in the elderly population compared with the Cockcroft-Gault equation. This may lead to 
dose selection errors for dabigatran, particularly for those with severe impairment, 
increasing the risk of adverse outcome. Hence, CKD-EPI and CKD-EPI-BSA equations 
should not be substituted for the Cockcroft-Gault equation in the elderly for the purpose 
of renal dosage adjustments. 
Also, an exposure response relationship for dabigatran etexilate was described, where the 
most effective response was observed when AUCss was in the range of 1.70 to 2.26 
mg*h/L. Therefore, it is feasible to develop guidance for optimal dosing to improve 
outcomes for patients with NVAF. 
Finally, there appears to be sub-optimal adherence to renal function monitoring for 
NVAF patients who receive more than 12 months treatment with dabigatran in the New 
Zealand primary care setting. Further investigation into whether an automated clinical 
decision support tool that reminds clinicians when to undertake renal function monitoring 
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1 General Introduction 
The broad aim of this thesis was to investigate aspects of dabigatran etexilate utilisation 
in New Zealand. More specifically, this thesis contributes to describing the outcomes of 
different estimates of renal function can influence outcomes, investigates adherence to 
recommended renal function monitoring and explores a novel technique for therapeutic 
drug monitoring. These topics have not been extensively investigated until now. 
The concept for this thesis developed out of my interest in clinical 
pharmacy/pharmacology, health informatics and the utilisation of large health databases 
to improve patient outcomes. Having worked as a pharmacist since the early 2000s, I 
have witnessed the improvement of health data recording in New Zealand. Databases 
have become much more robust and granular in nature and have allowed for improved 
utilization. This allows for the identification of the areas of greatest need and enables 
possible solutions to be developed. Overall, health inequities can be identified, and 
solutions can be investigated. 
This chapter covers the background of the introduction of dabigatran etexilate into New 
Zealand, including its clinical development and treatment of atrial fibrillation. Also 
included is an overview of the regulation and funding of medicines in New Zealand and 
the extensive capture and storage of health data in national administrative databases. 
This is a hybrid thesis cumulating from four manuscripts that have resulted from this 
study.




1.1.1 Mechanism of action 
Dabigatran etexilate, a non vitamin K antagonist oral anticoagulant (NOAC), is a low-
molecular-weight prodrug that exhibits pharmacological activity (Hankey et al., 2011) 
(Figure 1). Following oral administration, it is converted by esterases into the active 
form of dabigatran (Figure 2). Dabigatran is a highly selective, potent, competitive and 
reversible direct inhibitor of the active site of thrombin (Figure 3) (Baetz et al., 2008; Di 
Nisio et al., 2005; Eisert Wolfgang et al., 2010; Eriksson et al., 2009; Stangier, 2008). 
 
Figure 1 Chemical structure of the prodrug, dabigatran etexilate 




Figure 2 Chemical structure of active drug, dabigatran 
Thrombin is a plasma serine protease that plays a central role in coagulation and 
haemostasis (Stangier, 2008). Thrombin is produced by the proteolytic cleavage of 
prothrombin and catalyses the conversion of fibrinogen to fibrin, leading to thrombus 
formation (Stangier, 2008). In pathological conditions, thrombus formation can result in 
thrombotic complications, including deep-vein thrombosis (DVT), myocardial 
infarction, cerebrovascular disease and peripheral arterial disease (Husmann et al., 2007). 
Thromboembolic diseases are considered to be a major cause of morbidity and mortality 
both within New Zealand and worldwide (Murray et al., 1997), contributing to many 
hospitalisations (New Zealand Ministry of Health, 2019c). By interacting directly and 
exclusively with the active site of thrombin, dabigatran inactivates the fibrin-bound 
thrombin (Hauptmann et al., 1999). Reversible inhibition of thrombin leaves a small 
amount of free, enzymatically active thrombin available for control of 
haemostasis (Gustafsson et al., 2003). 
Thrombin has an active binding site and two secondary binding exosites (Huntington et 
al., 2003). At exosite one, substrates such as fibrin dock to promote orientation for active 
Chapter one - General introduction
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site binding while exosite two is the heparin-binding domain (Hankey et al., 2011). Being 
a univalent direct thrombin inhibitor that binds to the active site, dabigatran inactivates 
both fibrin-bound and unbound thrombin (Huntington et al., 2003). Indirect thrombin 
inhibitors such as unfractionated heparin and low-molecular-weight heparin cannot 
inhibit fibrin-bound thrombin (Hankey et al., 2011). The ability to inhibit fibrin-bound 
thrombin provides dabigatran with a theoretical advantage over the heparin class of drugs 
as the fibrin-bound thrombin can continue to trigger thrombus expansion (Weitz Jeffrey 
et al., 1998; Weitz et al., 1990). Through inhibition of thrombin, dabigatran prevents the 
conversion of fibrinogen into fibrin, positive feedback amplification of coagulation 
activation, cross-linking of fibrin monomers, platelet activation, and inhibition of 
fibrinolysis (Hankey et al., 2011) (Figure 3). 
 
Figure 3 Illustration showing the sites of action of new anticoagulants in the coagulation 
cascade. Vessel injury exposes tissue factor (TF), which interacts with activated factor 
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(F) VII to initiate coagulation. Cleavage of prothrombin (factor II) by the prothrombinase 
complex (factor Xa and its cofactor, factor Va) leads to the generation of thrombin (factor 
IIa). Thrombin converts fibrinogen to fibrin and provides positive feedback through 
activation of factors V, VIII, and XI in the coagulation cascade. Factors Va, VIIIa, and 
XIa promote the production of additional thrombin, which leads to cross-linkage of fibrin 
strands and the formation of a hemostatic plug. Thrombin also activates platelets through 
cleavage of the platelet membrane bound protease-activated receptors 1, 3, and 4. Factor 
Xa inhibitors block the conversion of prothrombin (factor II) to thrombin (factor IIa) by 
factor Xa incorporated within the prothrombinase complex (the complex of factor Xa and 
factor Va bound to the activated platelet surface). Thrombin inhibitors block thrombin-
mediated conversion of fibrin. These drugs also block thrombin-mediated feedback 
activation of factors V and VIII. Reprinted from Dabigatran Etexilate: A New Oral 
Thrombin Inhibitor, Circulation, Hankey GJ and Eikelboom JW (2011), 123: 1436-1450. 
DOI: 10.1161/circulationaha.110.004424 with permission from Wolters Kluwer Health, 
Inc. 
1.1.2 Formulation 
The prodrug dabigatran etexilate is used in oral formulations as this increases the 
bioavailability. This is due to the active drug dabigatran not being absorbed due to a 
highly lipophilic nature (Stangier, 2008). Currently dabigatran etexilate is available in 
capsule form in the strengths of 75mg, 110mg and 150mg (Boehringer Ingelheim (N.Z.) 
Limited, 2017). Steady state is achieved at around three days after multiple-dose oral 
administration in healthy volunteers (Stangier et al., 2007).  
1.1.3 Absorption 
Following oral administration, dabigatran etexilate is rapidly absorbed and completely 
hydrolysed to the active drug (i.e. dabigatran) by nonspecific ubiquitous esterases in the 
gut, plasma and liver (Stangier et al., 2007; Trocóniz et al., 2007). Bioconversion of 
dabigatran etexilate first occurs in the gut and, as a result, enters the portal vein as a mix 
of prodrug and active drug (Hankey et al., 2011). The absolute bioavailability following 
oral administration of dabigatran etexilate is only approximately 6.5%. Therefore, 
relatively high doses must be given to ensure that effective plasma concentrations are 
obtained (Blech et al., 2008; Stangier et al., 2007). Plasma concentrations and 
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anticoagulant effects are predictable and dose dependent with peak levels obtained within 
30 minutes to two hours following oral administration (Stangier et al., 2007; Stangier, 
Stähle, Rathgen, & Fuhr, 2008; Trocóniz et al., 2007). 
1.1.4 Metabolism 
Dabigatran etexilate undergoes bioconversion in the liver and approximately 20% is 
conjugated with guluronic acid and excreted in the biliary system (Ebner et al., 2010). 
Dabigatran etexilate is not metabolized by the cytochrome P450 enzymes or other 
oxidoreductases, but is a substrate for p-glycoprotein (Hankey et al., 2011). 
1.1.5 Half-Life 
Following oral administration, the mean terminal half-life of dabigatran is approximately 
eight hours post a single dose and varies from 12 to 14 hours after multiple 
dosing (Stangier et al., 2007; Stangier, Stähle, Rathgen, & Fuhr, 2008; Trocóniz et al., 
2007; Wolowacz et al., 2009). In older healthy volunteers, more typical of the patient 
population for which dabigatran is indicated, the half-life is about 13 hours (Stangier et 
al., 2010; Stangier, Stähle, Rathgen, & Fuhr, 2008). Half-life increases to over 24 hours 
in those patients with a creatinine clearance of less than 30 mL/min (Stangier et al., 
2010). 
1.1.6 Excretion 
Dabigatran is predominantly renally excreted, with up to 80% of circulating dabigatran 
excreted unchanged by the kidneys (Stangier et al., 2010; Stangier, Stähle, Rathgen, & 
Fuhr, 2008; Stangier, Stähle, Rathgen, Roth, et al., 2008). Therefore, in the presence of 
reduced renal function, the net result is an elevation in plasma concentrations of 
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dabigatran. (Stangier et al., 2010; Stangier, Stähle, Rathgen, & Fuhr, 2008). Current 
clinical guidance from the sponsor recommends that patients who are at risk of 
developing renal impairment should have their renal function monitored every 6 to 12
months (Boehringer Ingelheim (N.Z.) Limited, 2017). 
1.1.7 Drug Interactions 
Dabigatran etexilate is a substrate of the efflux permeability glycoprotein 
transporter (Hankey et al., 2011). This transporter is highly expressed in the intestines 
and kidneys and transports a number of molecules across the extracellular and 
intracellular membranes (Hankey et al., 2011). Plasma concentrations of dabigatran can 
be increased if co-administered with potent permeable glycoprotein inhibitors (for 
example amiodarone, ketoconazole, quinidine and verapamil) (Boehringer Ingelheim 
(N.Z.) Limited, 2017; Eisert Wolfgang et al., 2010). This occurs because there is a 
decrease in dabigatran reabsorption via permeability glycoprotein into the 
gastrointestinal tract (Eisert Wolfgang et al., 2010). Conversely, potent inducers (for 
example rifampicin) can reduce dabigatran plasma concentration by increasing its 
reabsorption via permeability glycoprotein into the gut (Eisert Wolfgang et al., 2010). 
The co-administration of dabigatran etexilate with other anticoagulants and antiplatelet 
drugs should be done with caution due to an increased risk of bleeding (Boehringer 
Ingelheim (N.Z.) Limited, 2017; Hankey et al., 2011). Whilst the co-administration with 
proton pump inhibitors (for example omeprazole, lansoprazole and pantoprazole) slightly 
reduces the mean area under the curve (AUC), there is no effect on efficacy and 
safety (Boehringer Ingelheim (N.Z.) Limited, 2017; Hankey et al., 2011). 
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1.1.8 The Randomised Evaluation of Long-Term Anticoagulation 
Therapy (RE-LY) Trial 
The recommendations for the use of dabigatran etexilate in AF are largely based on the 
results from the Randomised Evaluation of Long-Term Anticoagulation Therapy (RE-
LY) trial (Best Practice Advocacy Centre (bpacnz), 2011; Connolly et al., 2009). The RE-
LY trial was a phase III, multicentre, prospective, open-label, randomized trial with 
blinded evaluation of all outcomes (Connolly et al., 2009; Ezekowitz et al., 2009). The 
aim of RE-LY was to determine if dabigatran etexilate would be non-inferior to warfarin 
in patients with non-valvular atrial fibrillation (NVAF) (Connolly et al., 2009; Ezekowitz 
et al., 2009). This thesis builds on this work and adds real-world post-approval data that 
is important for further refining dosing regimens. 
In summary, RE-LY enrolled 18,113 patients with NVAF and at least one additional risk 
factor for stroke. The study spanned 44 countries and randomly assigned fixed doses of 
dabigatran etexilate (110mg or 150mg twice daily) or dose adjusted warfarin (target INR: 
2-3) (Connolly et al., 2009; Ezekowitz et al., 2009). After a median of two years follow-
up, the discontinuation rate for dabigatran etexilate was 21% and 17% for warfarin and 
20 patients were lost to follow-up (Connolly et al., 2009; Ezekowitz et al., 2009). 
The RE-LY trial concluded that when compared to warfarin, dabigatran etexilate dosed 
at 150mg twice daily reduced the rate of stroke, systemic embolism (warfarin, 
1.71%/year; dabigatran 150 mg twice daily, 1.11%/year; RR, 0.65; 95% CI, 0.52 to 0.81; 
P<0.001 for superiority) and death resulting for cardiovascular causes (RR, 0.85; 95% 
CI, 0.72 to 0.99) (Connolly et al., 2009; Connolly et al., 2010; Ezekowitz et al., 2009; 
Hankey et al., 2010). There was no significant difference in outcomes seen between 
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dabigatran 110 mg twice daily and warfarin (stroke or systemic embolism: warfarin, 
2.71%/year; dabigatran 110 mg twice daily, 1.54%/year; RR, 0.90; 95% CI, 0.74 to 1.10; 
P<0.001 for non-inferiority, P=0.30 for superiority) (Connolly et al., 2009; Connolly et 
al., 2010; Ezekowitz et al., 2009; Hankey et al., 2010) (Figure 4). 
 
Figure 4 Forest plot showing the results of the Randomized Evaluation of Long-Term 
Anticoagulant Therapy (RE-LY) trial for the primary outcome event of stroke or systemic 
embolism. The point estimate of each relative risk is indicated by a square; the 95% 
confidence interval (CI) of each relative risk by a horizontal line. Reprinted from 
Dabigatran Etexilate: A New Oral Thrombin Inhibitor, Circulation, Hankey GJ and 
Eikelboom JW (2011), 123: 1436-1450. DOI: 10.1161/circulationaha.110.004424 with 
permission from Wolters Kluwer Health, Inc. 
Additionally, the RE-LY trial concluded that when compared to warfarin, dabigatran 
etexilate 110mg twice daily significantly reduced the rate of major haemorrhage 
(warfarin, 3.57%/year; dabigatran 110 mg twice daily, 2.87%/year; RR, 0.80; 95% CI, 
0.70 to 0.93; P=0.003) (Connolly et al., 2009; Connolly et al., 2010). Also, there was no 
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significant difference in major haemorrhage seen between warfarin and dabigatran 
etexilate 150mg twice daily (warfarin, 3.57%/year; dabigatran etexilate 150 mg twice 
daily, 3.32%/year; RR, 0.93; 95% CI, 0.81 to 1.07; P=0.31 for superiority) (Connolly et 
al., 2009; Connolly et al., 2010).  
Furthermore, both doses were associated with fewer intercranial bleeds compared to 
warfarin (warfarin: 0.76% per year vs dabigatran etexilate 110 mg twice daily: 0.23% 
per year [RR: 0.30, 95% CI: 0.19 to 0.45] and dabigatran etexilate 150 mg twice daily: 
0.32% per year [RR: 0.41, 95% CI: 0.28 to 0.60]) (Connolly et al., 2010). However, there 
was a significant increase in gastrointestinal bleeding compared to warfarin with both 
doses (dabigatran etexilate 110 mg twice daily: 1.15% per year; RR: 1.36, 95% CI: 1.09 
to 1.70 and 150 mg twice daily: 1.07% per year; RR: 1.48, 95% CI: 1.18 to 
1.85) (Connolly et al., 2010). 
1.2 Regulation of medicines in New Zealand 
fined in the Medicines Act 
1981 (New Zealand Ministry of Health, 1981). It describes that when a product is 
administered to humans for a therapeutic purpose it is legally classified as a medicine. A 
therapeutic purpose is also defined in the Medicines Act and includes the treatment, 
diagnosis and prevention of disease or the modification of a physiological function (New 
Zealand Ministry of Health, 1981). 
1.2.1 Medsafe 
Medsafe is the New Zealand Medicines and Medical Devices Safety Authority and is a 
business unit of the New Zealand Ministry of Health (Medsafe, 2019a). It legally 
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classifies a product as a medicine when it is administered to humans for a therapeutic 
purpose. (Medsafe, 2019a). They have the responsibility to ensure that the therapeutic 
products available in New Zealand are safe for the population to use (Medsafe, 2019a). 
This is achieved by a rigorous registration process before the medicine is allowed to be 
marketed in New Zealand (Medsafe, 2019a). This process requires the sponsor of the 
medicine to submit data to Medsafe establishing its safety, efficacy and manufacturing 
quality.  Following registration and marketing of the medicine it is monitored by a post-
marketing surveillance programme (Medsafe, 2019a). Medsafe then monitors the safety 
of the medicine while it is in use (Medsafe, 2019a). Any medicines that are deemed to be 
hazardous are either recalled from the market or prescribers are advised about new safety 
information (Medsafe, 2019a). This information outlines what changes are required in 
care and/or prescribing to remove or limit the extent of the known hazard (Medsafe, 
2019a). For example, when it was identified that ranitidine formulations have the 
potential to contain the impurity of N-nitrosodimethylamine (NDMA), Medsafe released 
a safety alert outlining the issue with related information for health professionals, 
consumers and caregivers (Figure 5) (Medsafe, 2019d). 
 
Figure 5 Flow diagram following the registration and recall of ranitidine hydrochloride 
in New Zealand 
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In addition to monitoring the international literature, Medsafe monitors adverse reactions 
to medicines in New Zealand, tests medicines against quality standards and audits and 
licences medicine manufacturers (Medsafe, 2019a). 
1.2.2 The Medicines Classification Committee (MCC) 
The Medicines Classification Committee (MCC) is a ministerial advisory committee that 
makes recommendations to the New Zealand Minister of Health regarding the 
classification of medicines as prescription medicines, restricted medicines or pharmacy-
only medicines (Medsafe, 2019c). The MCC also considers and reports to the Minister 
of Health on any matter concerning the classification of medicines and access to 
medicines by health professionals and the public (Medsafe, 2019c). 
1.2.3 The Medicines Adverse Reactions Committee (MARC) 
The Medicines Adverse Reactions Committee (MARC) is a technical advisory 
committee that advises the New Zealand Minister of Health on the safety of approved 
medicines in New Zealand (Medsafe, 2019b). The MARC provides expert advice to the 
Director-General of Health and the Minister of Health in relation to the safety or efficacy 
of a medicine that is of concern (Medsafe, 2019b). They consider the safety information 
of medicines that are referred to them by Medsafe (Medsafe, 2019b). They provide expert 
advice on the interpretation of the information, the significance of the information in 
relation to the risk-benefit profile of the medicine and whether a regulatory intervention 
is required to minimise the risks from the use of the medicine (Medsafe, 2019b). 
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1.2.4 Period of medicine supply in New Zealand 
Most medicines in New Zealand can only be supplied in quantities that do not exceed 
more than three months (Medicines Regulations 1984, 1984). Exceptions to this include 
some controlled drugs than can only have a maximum supply of one month or oral 
contraceptives which cannot exceed six months (Medicines Regulations 1984, 1984). For 
Government funding purposes, some medicines can be supplied three months statim or 
may be restricted to monthly dispensing, requiring repeats from the first dispensing of 
the prescription to allow the full three months
information). 
1.3 Funding of Medicines in New Zealand 
This section outlines how medicines are funded in New Zealand. 
1.3.1 The Pharmaceutical Management Agency (PHARMAC) 
Established in 1993 by the New Zealand Government, PHARMAC decides which 
medicines, medical devices and related products are subsidised (Pharmaceutical 
Management Agency (PHARMAC), 2019b). At its inception, PHARMAC was given the 
role of providing medicines for the community within a budget set by the New Zealand 
Government (Pharmaceutical Management Agency (PHARMAC), 2019b). This role 
expanded over the following 25 years to include negotiating price and supply terms for 
both community and hospital medicines (Pharmaceutical Management Agency 
(PHARMAC), 2019b). Each year, PHARMAC receives a fixed budget from the New 
Zealand Government with the task to achieve the best health outcomes for New 
Zealanders by: 
Chapter one - General introduction
16 
 
Making sure that medicines and medical devices that are already available stay 
available; 
 Deciding which other medicines have the highest priority for acquiring new 
funding (Pharmaceutical Management Agency (PHARMAC), 2019b). 
Individual regions of New Zealand, defined as District Health Boards (DHB), are 
allocated annual funding for medicines by PHARMAC, which is based on population 
size (Pharmaceutical Management Agency (PHARMAC), 2019b). 
Currently PHARMAC funds approximately 1900 community medicines, 2500 hospital 
medicines and 6000 hospital medical devices (Pharmaceutical Management Agency 
(PHARMAC), 2019b). PHARMAC informs clinicians which medicines are available 
with subsidy and the level of subsidy. Levels of subsidy can vary between medicines and 
includes fully subsidised, part-subsidy and if a special authority or specialist 
recommendation is required for subsidy to be obtained (Pharmaceutical Management 
Agency (PHARMAC), 2019b). They also provide information on which formulations 
and strengths are available, how much can be prescribed at one time and if any access 
conditions are in place (Pharmaceutical Management Agency (PHARMAC), 2019b). On 
a monthly basis, PHARMAC releases a schedule of medicines that are funded in both the 
community and hospital settings. 
A medicine is eligible to be listed on this schedule after being approved for sale in New 
Zealand by Medsafe (Pharmaceutical Management Agency (PHARMAC), 2019b). 
Following that, a supplier or other applicant may make a submission for the medicine to 
be listed on the Schedule (Pharmaceutical Management Agency (PHARMAC), 2019b). 
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The Pharmacology and Therapeutics Advisory Committee (PTAC) decides whether a 
medicine is subsidised based on a number of decision criteria, including the clinical 
benefit and risk of the medicine, the availability and suitability of existing medicines and 
the economic impact to both the consumer and the health care sector (Pharmaceutical 
Management Agency (PHARMAC), 2019b). 
The indicative process for listing a new medicine on the New Zealand Pharmaceutical 
Schedule is outlined in Figure 6. 




Figure 6 The indicative process that may follow when a supplier or other applicant 
wishes a pharmaceutical to be funded on the New Zealand Pharmaceutical 
Schedule (Pharmaceutical Management Agency (PHARMAC), 2019b). 
1.4 Health administrative data capture in New Zealand 
In New Zealand there are a number of national health databases that can be 
accessed (New Zealand Ministry of Health, 2019a). The primary purpose of these 
databases is for health administration and financial reimbursement (New Zealand 
Ministry of Health, 2019a). However, the data contained in these databases can be used 
to support the decision-making process for policy development, funding and point of care 
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clinical decision making (New Zealand Ministry of Health, 2019a). These data is also 
increasingly being utilised for clinical research purposes. 
The data collected is attached to individual patients via encryption of their National 
Health Index (NHI) number (see below for more information)  (New Zealand Ministry 
of Health, 2019a). This allows data for individual patients to be linked across different 
databases. The encryption of the NHI allows for complete anonymity for individual 
patients (New Zealand Ministry of Health, 2009). 
This research project used three of these databases consisting of the Pharmaceutical 
Collection, the National Minimum Dataset (for hospital events) and the Best Practice 
Intelligence Dataset. The first two databases are national collections controlled by the 
Ministry of Health, and the latter is a private database maintained Best Practice Inc (Best 
Practice Inc). Specific details relating to these databases are discussed below. 
1.4.1 Pharmaceutical Collection Database 
The Pharmaceutical Collection (PC) began in 1992 and is a data warehouse that supports 
the management of pharmaceutical subsidies (New Zealand Ministry of Health, 2016b). 
It contains claim and payment information from pharmacists for subsidised dispensings 
in New Zealand. It is jointly owned by the Ministry of Health and PHARMAC (New 
Zealand Ministry of Health, 2016b). 
The PC captures approximately 99% of prescription medicines dispensed in the 
community and is therefore able to provide an accurate picture of medicine dispensing 
in New Zealand (New Zealand Ministry of Health, 2016b). The PC contains data on 
Chapter one - General introduction
20 
 
individual dispensings of medicines to a single patient and contains information about 
the medication name, strength, quantity supplied, number of repeat dispensings from the 
original prescription, medication cost and also basic demographic information about the 
patient (New Zealand Ministry of Health, 2016b). It should be noted that medications 
used in the community that are over the counter, non-subsidised (i.e. medicines not 
subsidised by PHARMAC) or in hospitals are not captured by the PC. 
As the PC is designed for medication reimbursements, clinical data about patients is not 
collected. Therefore, there is no information about the diagnosis or clinical reasoning for 
prescribing. Any subsidised co-dispensed medicines will be linked to the patient via their 
NHI number. Whilst the PC provides information about dispensed medicines, it does not 
record if the patient is actually taking the medicine (Statistics New Zealand, 2010). 
This study utilised the following variables from the PC: encrypted NHI, medicine name, 
dosage, formulation, dates dispensed, dispensing District Health Board, type of health 
professional prescribing, repeat code and days supplied. A description of the details 
relating to these variables is shown in Table 1. 
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Table 1 Variables used from the Pharmaceutical Collection
Variable Description 
Encrypted NHI number Patient identifier which has been 
encrypted to prevent patient identification 
(NB: encryption remains the same for the 
lifetime of the original NHI) 
Medicine name Chemical (generic) name of the active 
ingredient 
Dosage The number of units prescribed to be used 
at each use of the medication measured in 
Quantity units  
Formulation The name of the formulation that usually 
describes the form and strength. 
Date dispensed Date medicine was dispensed 
Dispensing District Health Board 
(DHB) 
District Health Board responsible for 
funding the services under the contract 
Type of health professional prescribing General practitioner, cardiologist, 
emergency medicine, internal medicine 
etc 
Days supply Total number of days supplied at each 
dispensing 
1.4.2 National Minimum Dataset (for hospital events) 
The National Minimum Dataset (NMDS) began in 1993 and is a national collection of 
public and private hospital discharge information, including coded clinical data for 
inpatients and day patients (New Zealand Ministry of Health, 2015). The NMDS is used 
by the Ministry of Health, District Health Boards (DHB), Primary Health Organisations 
(PHO), clinicians, researchers and members of the public for statistical information, 
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clinical benchmarking and planning and funding (New Zealand Ministry of Health, 
2015). It provides statistical information, reports and analyses about the trends in the 
delivery of hospital inpatient and day patient health services. 
The NMDS captures data on all patients discharged from day patient (greater than four 
hours) and inpatient care in publicly funded hospitals and publicly funded patients in 
private hospitals throughout New Zealand (New Zealand Ministry of Health, 2015). It 
does not cover privately funded activity in private hospitals. Also, the NMDS only 
captures data about patients who are admitted to hospital. Therefore, any patient who is 
discharged from emergency care within the hospital without a subsequent ward 
admission will not be included in this dataset. Furthermore, the data contained in the 
NMDS is derived from the clinical discharge summary and is therefore unlikely to 
contain data about pre-existing conditions. For example, in Chapters two, three and four 
any co-morbidities that may have impacted clinical outcome could not be investigated. 
This study utilised the following variables from the NMDS: encrypted NHI, birth date, 
ethnicity, patient sex, deprivation rating, ICD10 and date of clinical event. A description 
of the details relating to these variables is shown in Table 2. 
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Table 2 Variables used from the National Minimum Dataset (Hospital Events)
Variable Description 
Encrypted NHI number Patient identifier which has been 
encrypted to prevent patient identification 
Sex  
Birth date The date on which the person was born 
Ethnicity A social group whose members have one 
or more of the following four 
characteristics: share a sense of common 
origins claim a common and distinctive 
history and destiny possess one or more 
dimensions of collective cultural 
individuality feel a sense of unique 
collective solidarity 
Index of Deprivation Combines census data relating to income, 
home ownership, employment, 
qualifications, family structure, housing, 
access to transport and communications. 
Represented as deciles where 1 represents 
the areas with the least deprived scores 
and 10 the areas with the most deprived 
scores. 
ICD-10-AM code A code used to classify the clinical 
description of a condition 
Event start datetime The admission date and time on which a 
health care event began 
 
Chapter one - General introduction
24 
 
1.4.3 Best Practice Intelligence Database (BPI) 
Best Practice Intelligence (BPI) is a secure, internet based, reporting tool that extracts 
patient information from general practice electronic health care record (EHR) 
systems (Best Practice Inc). The primary service of BPI is to provide clinicians with 
reports generated for this data that focus on helping clinicians achieve health targets for 
their patients, all in real time. BPI can provide reports on a number of clinical 
performance indicators (Best Practice Inc). These include: 
 Summaries showing how a particular general practice is doing in specific areas; 
 Reports identifying patients to target for clinical screening; 
 Reports identifying patients with chronic conditions requiring clinical 
intervention (Best Practice Inc). 
BPI also functions to allow clinicians to track their progress to clinical goals, follow 
disease management for long term condition management and also identify high health 
needs patients (Best Practice Inc). This data is approved for research purposes that has 
meet the required ethics standards (Best Practice Inc). 
Unlike the PC and NMDS which are national data collections, BPI is a subscription-
based product and it utilised by approximately 16% of general practices in New 
Zealand (Best Practice Inc). 
This study utilised the following variables from BPI: encrypted NHI, sex, birth date, 
serum creatinine test result and date, height measurement result and date, weight 
measurement result and date, READ code and READ code date. READ codes are a coded 
thesaurus of clinical terms that provide a standard vocabulary for clinicians to report 
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patient clinical information (NHS Digital, 2018). A description of the details relating to 
these variables is shown in Table 3. 
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Table 3 Variables used from the Best Practice Intelligence database 
Variable Description 
Encrypted NHI number Patient identifier which has been 
encrypted to prevent patient identification 
Sex  
Birth date The date on which the person was born 
Serum creatinine test result The numerical result of serum creatinine 
test. 
Serum creatinine test result date The date on which the serum creatinine 
test was done 
Height measurement result The numerical result of height 
measurement 
Height measurement result date The date on which the height 
measurement was done 
Weight measurement result The numerical result of body-weight 
measurement 
Weight measurement result date The date on which the weight 
measurement was done 
READ code A code used to classify the clinical 
description of a condition 
READ code date The date on which the READ coded event 
began 
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1.4.4 National Health Index (NHI) number 
assigned 
a unique identifying code called the National Health Index (NHI) number (New Zealand 
Ministry of Health, 2009). The NHI system was introduced in 1992 and coverage is 
estimated to be 98% of  population (New Zealand Ministry of Health, 
2009). The NHI is regarded as the cornerstone of health information in New Zealand and 
was established to provide a mechanism for uniquely identifying every health user (New 
Zealand Ministry of Health, 2009). 
There are some limitations with the NHI system which need to be considered when 
undertaking related research. For example, there are some instances when a single 
individual can be assigned more than one NHI number. To address this, the Ministry of 
Health links the various NHI numbers when duplications are identified and only one NHI 
number will be deemed to be the primary with the others becoming secondary 
numbers (New Zealand Ministry of Health, 2009). Only the primary NHI is used for the 
analysis of health care information (New Zealand Ministry of Health, 2009). 
All EHR systems in New Zealand have the ability to identify patients by NHI number 
and therefore most systems are linked to the NHI number (New Zealand Ministry of 
Health, 2009). This allows for the correct identification of patients when they interact 
with the health care system (New Zealand Ministry of Health, 2009). Despite this ability 
for all EHR systems to use NHI numbers for patient identification there is no central EHR 
that acts as a repository for all heath information (New Zealand Ministry of Health, 
2009). This results in fragmented access to health information between health care 
service providers (New Zealand Ministry of Health, 2009). 
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1.4.5 Linking health administrative database in New Zealand 
While other countries have similarly collected health data in national databases, New 
Zealand is one of the only that links information predominately by one unique 
identifier (New Zealand Ministry of Health, 2009). This allows for the linked information 
to be readily used by researchers and policy makers to investigate such things as 
determining health care expenditure and tracking medicine use and health 
outcomes (New Zealand Ministry of Health, 2009). The use of individual NHI numbers 
allows for the following of a patient through the various databases to revel medicine use 
and health outcomes and has been utilised in other studies (Chan et al., 2011; Huria et 
al., 2018; Moodie, Jaine, Arnold, Bignall, et al., 2011; Moodie, Jaine, Arnold, Metcalfe, 
et al., 2011; Nishtala et al., 2016; Richards et al., 2018a, 2018b, 2019; Telfar Barnard et 
al., 2015; Wham et al., 2015). 
1.4.6 
etexilate usage 
This study is the first to utilise a large New Zealand General Practice database, being 
BPI, and linking individual patients to national heath administrative databases. By being 
able to link the databases, via encrypted NHI numbers, it is possible to identify patients 
prescribed and dispensed dabigatran etexilate. Then it is possible to analyse individual 
health data to monitor use, outcomes and investigate the effects of different variables on 
these. Specific information regarding the linking and utilization of these databases is 
described in chapters two, three, four and five. 
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1.4.7 Validity of using these databases for research 
h databases have been readily used to answer a number of health-
related research questions. In the area of medicine and pharmacy, these databases have 
been recently used to investigate medicine utilisation (Narayan et al., 2016; Richards et 
al., 2018b) and medicine-related harm (Fountain et al., 2019; Nishtala et al., 2016; 
Richards et al., 2018a, 2019). Using administrative databases for this form of research 
has a number of strengths, including no loss to follow-up, almost 100% coverage of the 
target populations, and it is inexpensive (Richards et al., 2018a). But the results can be 
limited to some extent by the available information in these datasets. For example, using 
these datasets to identify clinical events occurring is solely reliant on the information 
recorded within them and this is often limited to a simple clinically coded terminology. 
To gain a more complete understanding of the clinical events, access to more detailed 
clinical notes is required and this is not possible from the national administrative 
databases. Additionally, there are no reported studies that have linked the BPI general 
practice database to the Pharmaceutical Collection and NMDS to monitor medicine usage 
and outcomes. 
1.5  
Dabigatran etexilate first became registered with Medsafe in New Zealand in 2008 and 
gained full funding by PHARMAC in 2011. Its introduction resulted in rapid uptake by 
the sector, with it becoming the most used oral anticoagulant (New Zealand Ministry of 
Health, 2016b). When introduced to the market, dabigatran etexilate was promoted by 
the sponsor to have very few interactions with other medications and food, as well as 
having a minimal requirement for routine laboratory monitoring (Cohen, 2014). This 
provided both clinicians and patients with an attractive alternative to the only other 
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previously available oral anticoagulant, warfarin (Steffel et al., 2018). Warfarin requires 
regular blood tests to be taken to measure how long it takes for blood to clot (Blann et 
al., 2003). This is reported as a ratio called the international normalised ratio 
(INR) (Blann et al., 2003). Initially, INR testing is undertaken daily until the desired level 
of anticoagulation is achieved (Blann et al., 2003). If the INR is outside of the desired 
range, the dose of warfarin needs to be adjusted accordingly (Blann et al., 2003). Once 
stable, INR testing is likely to be measured every one to two weeks or possibly extended 
to every four to eight weeks if the patient is stable (Blann et al., 2003). Also, warfarin 
has numerous interactions with other medications and food (Blann et al., 2003). As 
dabigatran etexilate is promoted to not have these limitations, this can in part, explain for 
its rapid adoption by the health care community in New Zealand. 
1.5.1 Therapeutic indications 
Currently, in New Zealand, dabigatran etexilate is indicated for the: 
1. prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation; 
2. prophylaxis of venous thromboembolism following total hip replacement 
surgery; 
3. prophylaxis of venous thromboembolism following total knee replacement 
surgery; 
4. treatment of deep-vein thrombosis and pulmonary embolism; 
5. prevention of recurrent deep-vein thrombosis or pulmonary 
embolism (Boehringer Ingelheim (N.Z.) Limited, 2017). 
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1.5.2 New Zealand Usage 
Although there is some international data on the usage of dabigatran etexilate, specific 
New Zealand usage and prescribing trends are largely unknown (European Medicines 
Agency, 2011; Loo et al., 2017; Weitz et al., 2015; Yao et al., 2016). While New Zealand 
data exists relating to persistence and adherence there is limited available data relating to 
the adverse outcomes (such as haemorrhage or thromboembolism) experienced for 
patients prescribed dabigatran etexilate (Harper et al., 2018; Metcalfe et al., 2012). 
Finally, there are no reported investigations into what effects patient demographic 
characteristics have on the outcomes from dabigatran etexilate treatment at regional or 
national levels. 
1.6 Atrial fibrillation 
A main indication that dabigatran etexilate is utilised for, in New Zealand, is the 
treatment of non-valvular atrial fibrillation (NVAF) (Boehringer Ingelheim (N.Z.) 
Limited, 2017). NVAF affects up to 5% of people in New Zealand aged over 65 
years (Tomlin et al., 2016). Patients with AF have a higher risk of mortality, with a four 
to five-fold increased risk of stroke, a three-fold increased risk of heart failure and two-
fold increased risks of myocardial infarction and dementia compared to those 
without (Gorenek et al., 2017). 
AF is an increasingly common health problem that affects approximately 2% of the 
general population in Western countries (Chugh Sumeet et al., 2014; Heeringa et al., 
2006; Lowres et al., 2013). Due to an aging population and better detection methods for 
AF its prevalence appears to be increasing (Martinez et al., 2015; Schnabel et al., 2015) 
and is expected to double within 20 years (Chugh Sumeet et al., 2014). 
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Non-communicable disease patterns in New Zealand tend to reflect those seen in other 
Western countries (Gu et al., 2018). Gu et al conducted a retrospective cohort study of 
37 New Zealand general practices (n=135,840) and reported that, there was a higher 
while the Pacific population has an intermediate prevalence (Gu et al., 2018). 
earlier than the rest of the population (Gu et al., 2018). This highlights the need for 
comprehensive management strategies which includes appropriate medication 
prescribing and adherence (Gu et al., 2018). 
1.6.1 Aetiology 
Atrial fibrillation (AF) is an irregular heartbeat that can lead to blood clots, stroke, heart 
failure and other heart related complications (Lip et al., 1995). During AF there is a 
haemodynamic disturbance that results from the absence of atrial systole and from rapid 
and irregular ventricular response (Lip et al., 1995). As a result, there is a loss of cardiac 
output, and this is important in patients with increasing age and/or progressive 
impairment of left ventricular contraction for whom atrial systole contributes 
increasingly towards the overall stroke volume (Lip et al., 1995). During AF, patients 
experience a rapid heart rate that results in a reduction in the diastolic filling interval (Lip 
et al., 1995). The additional loss of the sequential atrioventricular contraction mechanism 
in atrial fibrillation may lead to a dramatic reduction in cardiac output and to other 
haemodynamic disturbances (Andreotti et al., 2015). 
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1.6.2 Adverse outcomes 
Patients with AF are at a greater risk of thromboembolic stroke, heart failure and sudden 
cardiac death  (Kellerman et al., 2019). AF is also associated with greater cognitive 
decline and risk of dementia (Kellerman et al., 2019). However, apart from stroke 
prevention and rate and rhythm control, there is currently a lack of effective prevention 
strategies for dementia and sudden cardiac death (Kellerman et al., 2019). 
Stroke 
There is a fivefold increased risk of stroke for patients with AF. AF occurs in 
approximately 15% of patients presenting with acute stroke (Lip et al., 1995). Also, the 
risk of stroke for AF patients is approximately 5% a year, and the epidemiological 
evidence suggests that this risk increases with age, raised blood pressure, and other 
evidence of heart disease (Lip et al., 1995). There is also an increased risk of recurrent 
stroke for these patients (Lip et al., 1995). Additionally, patients with acute stroke and 
atrial fibrillation have a significantly higher mortality than those patients with a normal 
sinus rhythm (Lip et al., 1995). This higher mortality is explained partly by the 
association of atrial fibrillation with large, total anterior cerebral infarcts, probably due 
to occlusion of the middle cerebral artery (Lip et al., 1995). 
Stroke is the second most common cause of death in New Zealand (Stroke Foundation 
New Zealand, 2019). The 2018/19 New Zealand Health Survey reported that the 
unadjusted prevalence of stroke (diagnosed, excluding transient ischaemic attacks) in the 
adult population was 1.6% which is an estimated 64,000 people (New Zealand Ministry 
of Health, 2019b). Approximately 24 strokes occur each day in New Zealand and the 
incidence of stroke increases with age with three quarters of people who have a stroke 
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being over 65 years of age (Stroke Foundation New Zealand, 2019). Figure 7 shows the 
age distribution of stroke (diagnosed, excluding transient ischaemic attacks) as reported 
in the 2018/19 New Zealand Health Survey. The average age of onset of stroke is around 
ten to 15 Peoples compared to New Zealand 
Europeans (Feigin et al., 2015; Stroke Foundation New Zealand, 2019). The unadjusted 
prevalence of stroke (diagnosed, excluding transient ischaemic attacks) in the adult 
population is 2.1% (New Zealand Ministry of Health, 2019b). This can be partially 
attributed to there being an increasing prevalence of hypertension, myocardial infarction, 
diabetes mellitus, AF, and low usage of anticoagulants in AF in the ri 
population (Feigin et al., 2015). A previous randomized controlled trail conducted in 
New Zealand investigated a novel approach to improve the low adherence to secondary 
stroke prevention via motivational interviewing (Barker-Collo et al., 2015). This trial 
showed that motivational interviews improved self-reported medication 
adherence (Barker-Collo et al., 2015) and it is possible that this could be effective for 
improving the low usage o  




Figure 7 Stroke (diagnosed, excluding transient ischaemic attacks): Age distribution 
(2018/19). Source New Zealand Health Survey (New Zealand Ministry of Health, 
2019b). 
Stroke is a major cause of serious adult disability in New Zealand (Stroke Foundation 
New Zealand, 2019). There is an estimated 60,000 stroke survivors in New Zealand, 
many of whom are disabled and require significant daily support, such as institutional 
care, as a result (Stroke Foundation New Zealand, 2019). Approximately two-thirds of 
stroke survivors will have some level of disability one year after a stroke with half being 
permanently disabled (Warlow et al., 2003). 
It has been estimated that approximately 11% of patients who suffer an ischaemic stroke 
and 30% of those who suffer a haemorrhagic stroke will die within the first 
month (Warlow et al., 2003). 




AF allows for the formation of intracardiac thrombus, which may result in stroke and 
thromboembolism (Lip et al., 1995). Thrombi often form in the left atrial appendage 
while right atrial thrombus with subsequent pulmonary thromboembolism is a rare 
complication (Lip et al., 1995). 
Heart failure 
In approximately 35% of AF patients, heart failure can develop and this often occurs after 
the sudden onset of fast AF (Lip et al., 1995). This is often more pronounced if there is 
pre-existing reduced left ventricular function and heart disease (Lip et al., 1995). For 
these patients, it is possible that AF may be a precursor for increased mortality and 
increase the risk of thromboembolism (Lip et al., 1995). 
1.6.3 Atrial fibrillation treatment options in New Zealand 
Most patients in New Zealand with AF are managed in the primary care setting by their 
general practitioner (Best Practice Advocacy Centre (bpacnz), 2017b). As AF patients 
have an increased risk of thromboembolism, including stroke or systemic embolism they 
should be assessed for the need to be treated with an anticoagulant (Best Practice 
Advocacy Centre (bpacnz), 2017b). During the timeframe of this study, the only available 
funded treatment options funded by PHARMAC were warfarin sodium and dabigatran 
etexliate. Both rivaroxaban and apixaban (which are now available in New Zealand) are 
not discussed in this thesis as they were not available via subsidy in New Zealand during 
the specified timeframe of this study. Therefore, there was no available data in the 
Pharmaceutical Collection relating to these two medications and were therefore not 
within the scope of this study. 
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1.6.4 Assessing the need for an anticoagulant 
International guidelines, adopted by New Zealand, recommend that the need for an 
anticoagulant to reduce the risk of ischaemic stroke in AF patients is assessed using the 
CHA2DS2-VASc (congestive heart failure, hypertension, 
mellitus, history of stroke or thromboembolism, vascular disease, age 65 74 years and 
female sex) score (Table 4). The risk of ischaemic stroke increases with increasing 
CHA2DS2-VASc score and data indicates that patients with higher CHA2DS2-VASc 
scores benefit more from treatment with warfarin sodium for both females (Figure 8) 
and males (Figure 9) (Allan et al., 2017). It has been reported that similar reductions in 
ischemic stroke would be expected for dabigatran etexliate (Kirchhof et al., 2013; Pisters 
et al., 2013). 
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Table 4 Clinical risk factors for stroke, transient ischaemic attack, and systemic 
embolism in the CHA2DS2-VASc score. Adapted from 2016 ESC Guidelines for the 
management of atrial fibrillation developed in collaboration with EACTS, European 
Heart Journal, Kirchhof P, Benussi S, Kotecha D, et al. (2016) 37: 2893-2962. DOI: 
10.1093/eurheartj/ehw210, with permission from Oxford University Press 
CHA2DS2-VASc risk factor Points 
Congestive heart failure 
Signs/symptoms of heart failure or 
objective evidence of reduced left 
ventricular ejection fraction 
+1 
Hypertension 
Resting blood pressure >140/90 mmHg 
on at least two occasions or current 
antihypertensive treatment 
+1 
Age 75 years or older +2 
Diabetes mellitus 
Fasting glucose >125 mg/dL (7 mmol/L) 
or treatment with oral hypoglycaemic 
agent and/or insulin 
+1 
Previous stroke, transient ischaemic 
attack, or thromboembolism 
+2 
Vascular disease 
Previous myocardial infarction, 
peripheral artery disease, or aortic plaque 
+1 
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Age 65 74 years +1
Sex category (female) +1 
CHA2DS2-VASc = Congestive Heart failure, hypertension, Age 75 (doubled), 
Diabetes, Stroke (doubled), Vascular disease, Age 65 74, and Sex (female). 
 
 
Figure 8 Incidence rates (95% CIs) per 100 person-years of ischaemic stroke in females 
by CHA2DS2-VASc scores, and use of warfarin. Individuals could contribute follow-up 
time to periods with and without warfarin. Reprinted from Net clinical benefit of warfarin 
in individuals with atrial fibrillation across stroke risk and across primary and secondary 
care, Heart, Allan V, Banerjee A, Shah AD, et al (2017) 103: 210-218, DOI: 
10.1136/heartjnl-2016-309910 with permission from BMJ Publishing Group Ltd. 
 




Figure 9 Incidence rates (95% CIs) per 100 person-years of ischaemic stroke in males 
by CHA2DS2-VASc scores, and use of warfarin. Individuals could contribute follow-up 
time to periods with and without warfarin. Reprinted from Net clinical benefit of warfarin 
in individuals with atrial fibrillation across stroke risk and across primary and secondary 
care, Heart, Allan V, Banerjee A, Shah AD, et al (2017) 103: 210-218, DOI: 
10.1136/heartjnl-2016-309910 with permission from BMJ Publishing Group Ltd. 
Current recommendations are that an anticoagulant should be considered for females 
with a CHA2DS2-VASc score of two or greater and males with a score of one or 
greater (Kirchhof et al., 2016; National Institutes for Health and Care Excellence (NICE), 
2014). Females with no risk factors other than their sex and males with no risk factors 
should not be treated with an anticoagulant as the risk of stroke is low, with rates of 
ischaemic stroke less than 1 per 100 people per year (Allan et al., 2017). Therefore, the 
benefit from the use of an anticoagulant is unlikely to outweigh the risks of 
treatment (Allan et al., 2017). 
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1.6.5 Assessing bleeding risk 
AF patients with an increased risk of stroke also have an increased risk of having a major 
bleed when treated with an anticoagulant (Kirchhof et al., 2016). Currently, the HAS-
BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or 
predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol 
concomitantly) score is utilised to assess the risk factors for bleeding and help guide 
clinicians to manage bleeding risk (Table 5) (Pisters et al., 2010). The bleeding risk for 
a patient increases with increasing HAS-BLED scores (Friberg et al., 2012; National 
Institutes for Health and Care Excellence (NICE), 2014). However, specific cut-offs for 
identifying patients who should not receive anticoagulant therapy are not 
defined (Kirchhof et al., 2016). This is predominantly due to the consequences of a stroke 
having a greater severity than that compared to a bleed (Kirchhof et al., 2016). Therefore, 
consideration for the use of an anticoagulant should primarily be based on the CHA2DS2-
VASc score with the HAS-BLED score being used to balance the risk benefit profile, 
identify any factors that could possibly alter bleeding risk and identify those patients who 
could benefit from more frequent follow-up or intensive management (National Institutes 
for Health and Care Excellence (NICE), 2014).  
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Table 5 Clinical Characteristics Composing the HAS-BLED Bleeding Risk Score. 
Adapted from A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of 
Major Bleeding in Patients With Atrial Fibrillation The Euro Heart Survey, CHEST, 
Pisters R, Lane DA, Nieuwlaat R, et al. (2010) 38: 1093-1100. DOI: 
https://doi.org/10.1378/chest.10-0134, with permission from The American College of 
Chest Physicians. Published by Elsevier Inc 
Clinical Characteristics Points 
Hypertension 
Systolic blood pressure greater than 
160mmHg or uncontrolled blood pressure  
+1 
Abnormal renal or liver function 
One point each for renal or liver 
impairment, e.g. liver disease or 
aminotransferase levels greater than 3 
times the upper limit of normal 
+1 or +2 
Stroke 
Previous history of stroke 
+1 
Bleeding 
A previous history or predisposition to 
bleeding, such as anaemia 
+1 
Labile INR 




Age greater than 65 years 
+1 
Drugs or alcohol +1 or +2 
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One point each for concomitant use of 
medicines that predispose patients to 
bleeding, e.g. anti-platelets or non-
steroidal anti-inflammatory drugs; or 
alcohol or drug use, e.g. eight or more 
standard drinks per week 
HAS-BLED=Hypertension, Abnormal renal/liver function, Stroke, Bleeding history 
or predisposition, Labile international normalized ratio, Elderly (>65 years), 
Drugs/alcohol concomitantly 
INR=international normalized ratio 
1.7 Renal function estimation and dabigatran etexilate dosing 
It has previously been shown that using varying methods to estimate a patie
function can result in different doses of dabigatran etexilate being prescribed (Dowling 
et al., 2013; Hellden et al., 2013; Hudson et al., 2014; MacCallum et al., 2013; Manzano-
Fernández et al., 2015; Pérez Cabeza et al., 2018). As stated earlier, approximately 80% 
of dabigatran etexilate is eliminated by renal excretion (Stangier et al., 2010; Stangier, 
Stähle, Rathgen, & Fuhr, 2008; Stangier, Stähle, Rathgen, Roth, et al., 2008). This 
highli
appropriately when making dosage decisions. Incorrect dosing of NOACS (including 
dabigatran etexilate) have been shown have a relationship with adverse clinical 
outcomes (Steinberg et al., 2016; Yao et al., 2017). Currently, there is no reported data 
showing how the use of different renal function estimators affects NVAF patient 
outcomes who are prescribed dabigatran etexilate. 




function. These include Cockcroft-Gault (Cockcroft et al., 1976) (Equation 1), the 
chronic kidney disease epidemiology initiative (CKD-EPI) (Equation 2) (Levey et al., 
2009)  (Equation 3) (Levey et 
al., 2006), the abbreviated MDRD equation (4) (MDRD-4) (Equation 4) (Levey et al., 
2006) and the Chronic Kidney Disease Epidemiology Collaboration adjusted for BSA 
(CKD-EPI-BSA) equation (Equation 5). The Cockcroft-Gault equation (Cockcroft et 
al., 1976) has been used for over 40 years to evaluate renal function by estimating 
creatinine clearance (CrCl). CKD-EPI, MDRD and MDRD-4 provide estimates of 




CrCl = creatinine clearance, 
age = age in years, 
weight = weight in kg, 
SCr = serum creatinine (expressed in mg/dL). 
 









age = patient age in years, 
SCr = serum creatinine (expressed in mg/dL). 
 
Equation 2: CKD-EPI 
 





eGFR = estimated glomerular filtration rate, 
age = patient age in years, 
BUN = blood urea nitrogen (expressed in mmmol/L) 
Alb = serum albumin (expressed in g/dl) 
SCr = serum creatinine (expressed in mg/dL). 
 




eGFR = estimated glomerular filtration rate, 
age = patient age in years 
SCr = serum creatinine (expressed in mg/dL). 
 
Equation 4: MDRD-4 
 
Where: 





age = patient age in years, 
SCr = serum creatinine (expressed in mg/dL), 
BSA= individuals body surface area, 
. 
 
Equation 5: CKD-EPI-BSA 
 
 
1.7.2 Utilisation of Equations 
Currently, CKD-EPI is the renal function estimate of choice for clinical care in New 
Zealand and is routinely reported in electronic health record patient notes following 
plasma creatinine blood tests (Johnson et al., 2012). This has arisen because it is seen to 
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give the best estimation of glomerular filtration rate of the available equations (Michels 
et al., 2010). As a result of this, discrepancies between how renal function is estimated 
in clinical care compared to the sponsor
likely due to current guidance from the two major international regulators (being the 
United States Food and Drug Administration (FDA) (U.S. Department of Health and 
Human Services Food and Drug Administration, 2012) and European Medicines Agency 
(EMA) (European Medicines Agency, 2015) not specifying one definite method of 
estimation. Consequently, there now appears to be worldwide inconsistency in dosage 
recommendation for patients with impaired renal function. 
As CKD-EPI is the first choice renal function estimate in New Zealand it is probable that 
it is being used to guide dabigatran etexilate dosing (Howey et al., 2013) despite the 
clinical guidance from the sponsor 
the Cockcroft Gault equation (Boehringer Ingelheim (N.Z.) Limited, 2017; January et 
al., 2014; Steffel et al., 2018)
may be different to the recommended dose if the Cockcroft-Gault equation was utilised. 
Further complicating this issue is that when eGFR is used to guide dosing, there is a need 
to ad
body-weight (Jones, 2011). The failure to adjust for BSA has the potential to lead to 
incorrect renal function estimation and result in an inappropriate dose selection. 
As a consequence of these factors there is confusion experienced by clinicians as to what 
is the best approach in clinical practice (Chin, Wright, & Florkowski, 2014; Jones, 2011). 
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1.7.3 Studies investigating renal function estimators and dabigatran 
etexilate 
Previous studies have shown that using different estimators of renal function can result 
in different doses of dabigatran etexilate being prescribed to patients (Table 6) (Cartet-
Farnier et al., 2017; Dowling et al., 2013; Hellden et al., 2013; Higdon et al., 2017; 
Hudson et al., 2014; Kruger et al., 2017; Kucey et al., 2016; Lum et al., 2013; MacCallum 
et al., 2013; Manzano-Fernández et al., 2015; Pérez Cabeza et al., 2018; Schwartz, 2016). 
Additionally, Chin et al (2014) investigated the correlation between trough plasma 
dabigatran concentrations and estimates of glomerular filtration rate based on creatinine 
and cystatin C (a biomarker of kidney function) (Chin, Wright, Zhang, et al., 2014). 
Evidence investigating the association of using different estimators of renal function and 
the impact on patient outcomes is absent from the literature. 
The majority of these studies have involved retrospective data collection from medical 
treatment facilities located in Europe and North America  (Cartet-Farnier et al., 2017; 
Higdon et al., 2017; Kruger et al., 2017; Kucey et al., 2016; Lum et al., 2013; MacCallum 
et al., 2013; Manzano-Fernández et al., 2015; Pérez Cabeza et al., 2018). These studies 
compare the difference in dosing recommendations when the Cockcroft-Gault equation 
is substituted with an alternative such as CKD-EPI, MDRD or variations of the 
Cockcroft-Gault equation. All these studies conclude that the substitution of the 
Cockcroft-Gault equation for alternatives can result in a different estimation of renal 
function and thus potentially result in a dose discordance. Two of these studies did not 
limit participants to only AF patients (Cartet-Farnier et al., 2017; Higdon et al., 2017), 
but as these are data simulations of renal function estimation, it should not introduce 
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related bias to the results. None of the studies investigated the impact on patient outcomes 
if an alternative estimator was used. 
Three other studies that utilised data collected from other databases or studies for 
alternative research purposes reported the same conclusions as above (Dowling et al., 
2013; Hellden et al., 2013; Schwartz, 2016). Helldén et al (2013) utilised data from six 
studies in the literature investigating renal function among the elderly (Hellden et al., 
2013). This study only compared the performance of Cockcroft-Gault equation with the 
MDRD-4 equation but also showed that, if used, MDRD-4 would result in higher doses 
of dabigatran etexilate. Schwartz et al (2016) utilised renal function data from two health 
related databases being, the National Health and Nutrition Examination Survey 
(NHANES) 2011/12 and a research database consisting of medically stable adults 
enrolled in research studies approved by the University of California at San Francisco 
human research committee from 2012 to 2014 (including very elderly and nursing home 
residents and excluded people undergoing dialysis, with active malignancies, or with 
hypercalcemia) (Schwartz, 2016). Dowling et al (2013) conducted a retrospective cross-
sectional study using data randomly selected from the Baltimore Longitudinal study of 
aging and compared the performance of Cockcroft-Gault equation with the MDRD and 
CKD-EPI equations (Dowling et al., 2013). This study showed that both the MDRD and 
CKD-EPI equations significantly overestimated renal function, compared to the 
Cockcroft-Gault equation, in elderly individuals. They concluded that this overestimation 
leads to dose calculation errors for many drugs (including dabigatran etexilate), 
particularly in individuals with severe renal impairment. It should be noted that these 
studies did not limit participants to only AF patients, but as these are data simulations of 
renal function estimation, it should not introduce related bias to the results. 
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Chin et al (2014) investigated the correlation between trough plasma dabigatran 
concentrations and estimates of glomerular filtration rate based on creatinine and cystatin 
C (Chin, Wright, Zhang, et al., 2014). Venous blood samples were collected 10 to 16 
hours post dosing of dabigatran to determine renal function biomarkers and dabigatran 
concentrations. They concluded that the four different estimates of renal function 
investigated explained 32 to 47% of the variability in trough plasma dabigatran 
concentration after other relevant covariates were considered. Unlike the other studies 
included in this section, this study concluded the dosing recommendations between the 
four different estimates of renal function investigated showed high agreement in 
simulated dabigatran etexliate dosing. This high agreement between the equations was 
attributed to over 92% of the participants having a GFR of greater than 50 mL/min, with 
a median GFR of approximately 90 mL/min. Therefore, the majority of the differences 
in estimated GFR between the four equations were above the 50 mL/min threshold for 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.8 Dabigatran etexilate and renal function monitoring
Currently, in New Zealand, data relating to adherence to appropriately timed renal 
function testing for dabigatran etexilate are lacking. Previously published audits of New 
Zealand dabigatran etexilate patients have shown 100% adherence to renal function 
testing protocols at treatment initiation and between 63 to 90% adherence in the first year 
for those being treated for more than one year (Table 7) (McBain et al., 2018; Thorne et 
al., 2015). In relation to the testing in the first year, the audits investigated if a patient 
receiving dabigatran etexilate had a renal function test undertaken any time in the 12
months following treatment initiation (Best Practice Advocacy Centre (bpacnz)). Current 
clinical guidance recommends that patients undergo tests every 12 months or more often 
if clinically indicated (Best Practice Advocacy Centre (bpacnz), 2011; Boehringer 
Ingelheim (N.Z.) Limited, 2017; Medsafe Pharmacovigilance Team, 2015). Therefore, 
as these audits do not account for the proximity of the test to the 12 month anniversary 
of treatment initiation it is not possible to determine if testing is being undertaken at these 
clinically appropriate times. Thus, there may be misrepresentation of the number of 
patients undergoing renal function testing at clinically appropriate times. Furthermore, 
there is a lack of published data in the literature that describes when clinicians are 
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1.9 Dabigatran etexilate therapeutic drug monitoring (TDM) 
Dabigatran etexilate was developed and marketed to be used in fixed dose regimens 
without the need for dose titration or monitoring of blood levels (Cohen, 2014). This was 
considered to be one of the major advantages over the use of warfarin (Cohen, 2014). 
Throughout the development, registration and marketing of dabigatran etexilate the claim 
that there is no need to monitor drug levels has been at the forefront (Cohen, 2014). This 
is considered to have been a factor in the cost benefit evaluations of pharmaceutical 
funding bodies (including PHARMAC) resulting in the widespread uptake of the 
drug (Cohen, 2014). But this claim that there is no need for therapeutic drug monitoring 
(TDM) has become controversial (Cohen, 2014). In an investigation undertaken by the 
British Medical Journal, it was reported that recommendations for the use of dabigatran 
etexilate may have been flawed as regulators did not see evidence from the clinical trials 
showing that TDM could improve safety (Cohen, 2014). This improvement involved 
major bleeds possibly being reduced by 30 to 40% when compared with well controlled 
warfarin use (Cohen, 2014). 
Certain clinical situations would benefit from assessment of the anticoagulation effect of 
dabigatran etexilate, for example: those who are bleeding, before and after administration 
of the dabigatran-specific antidote idarucizumab, evaluation of therapy failure in case of 
thrombosis, renal failure, before emergency surgery, before potential thrombolysis in 
ischemic stroke, at extremes of bodyweight, concomitant use of drugs known to affect 
the pharmacokinetics of dabigatran etexilate, and in cases of suspected 
nonadherence (Comuth et al., 2018). 
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Current recommended monitoring by the sponsor for anticoagulant effect and increased 
risk of bleeding can possibly be detected via elevated coagulation tests, such as thrombin 
time (TT), ecarin clotting time (ECT), and activated partial thromboplastin time 
(aPTT) (Boehringer Ingelheim (N.Z.) Limited, 2017). However, there are limitations to 
the aPTT, such as the test having limited sensitivity making it unsuitable for precise 
quantification of the anticoagulant effect (Douxfils et al., 2017). Also, the ECT test not 
being readily available or useful in the absence of standardisation means that there is 
limited use of these tests in clinical practice (Douxfils et al., 2017). TT is a very useful 
test for detecting low levels of dabigatran etexilate in plasma (Chin, Wright, Patterson, 
et al., 2014) but becomes rapidly unclottable in the presence of low dabigatran etexilate 
concentrations (Amiral et al., 2016). Thus, TT cannot be used for the overall expected 
dabigatran etexilate concentration measurement (Amiral et al., 2016). 
In relation to treatment failure, it has been reported that only a limited exposure-response 
analysis could be undertaken for venous thromboembolism (VTE) due to the low number 
of endpoint events for VTE patients and only pharmacokinetic data being available from 
clinical trials  (Committee for Medicinal Products for Human Use (CHMP), 2014). As a 
consequence, no guidance has been provided to clinicians relating to the monitoring of 
patients for possible subtherapeutic treatment (Committee for Medicinal Products for 
Human Use (CHMP), 2014). 
Currently there are no reported reference ranges for dabigatran TDM for use in clinical 
practice in the literature. The measurement of dabigatran plasma concentrations is now 
feasible with point of care testing (Poli et al., 2017; Rottenstreich et al., 2018) but the 
thresholds have yet to be validated. Validation is essential to ensure that clinical decisions 
based on dabigatran plasma levels represent the balance between avoiding bleeding and 
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preventing thrombosis (Douxfils et al., 2017). While it has been shown that there is an 
association between plasma concentrations and bleeding risk, the clear cut-offs for 
bleeding and thromboembolism and/or cerebrovascular accident (CVA) risk are not yet 
established (Douxfils et al., 2017). 
1.10 Health equity issues in New Zealand 
over the past decades (New Zealand Ministry of Health, 2018). Despite this improvement 
there remains persistent disparities in health access, quality of service and 
outcomes (New Zealand Ministry of Health, 2018). M ori and Pacific Peoples and those 
in low socioeconomic groups are still the most disadvantaged in society today (New 
Zealand Ministry of Health, 2018). There is extensive documentation that inequities exist 
in medication access and usage, health outcomes, disease or health risks between ethnic 
groups both in New Zealand and internationally (Marrone, 2007; Meghani et al., 2012; 
Metcalfe et al., 2013; New Zealand Ministry of Health, 2017; Papaarangi et al., 2007; 
Pharmaceutical Management Agency (PHARMAC), 2019a). 
Comparison of the New Zealand health care system internationally shows that it is 
comprehensive and, while it generally performs well, there are significant health 
inequities (Pharmaceutical Management Agency (PHARMAC), 2019a). Health 
outcomes in New Zealand have a graded association with area-based deprivation (Abas 
et al., 2006; Atkinson et al., 2014; Barnett et al., 2003; Utter et al., 2010). There is also 
evidence of inequitable health care by race and ethnicity in New Zealand (Metcalfe et al., 
009). For example, the Commonwealth Fund ranks New Zealand 
fourth out of eleven wealthy countries for performance but only eighth for 
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equity (Pharmaceutical Management Agency (PHARMAC), 2019a). The 2018/19 New 
Zealand Health Survey also reports Peoples and those living in the 
most deprived areas generally report poorer health than others (New Zealand Ministry of 
Health, 2019b). Additionally, the l  populations is 
lower ic peoples are also two to three times more likely to die of 
conditions that could have been avoided if effective and timely health care had been 
available (Cumming, 2017). The gap between  and non-  in relation to life 
expectancy at birth is 7.1 years (6.8 
males) (Statistics New Zealand, 2015). There is also 
Asian Peoples experience higher rates of racism, which has been linked to negative 
patient experiences (Harris et al., 2012).  
Social determinants of health are important drivers of health inequities (i.e. the unfair 
and avoidable differences in health status seen within and between 
countries) (Commission on Social Determinants of Health, 2008; World Health 
Organization, 2019). The social determinants of health are defined as the conditions in 
which people are born, grow, live, work and age and are shaped by the distribution of 
finances, power and resources at global, national and local levels (World Health 
Organization, 2019). It is also documented, that certain population groups are more likely 
to face health challenges than other groups (Marmot, 2005; New Zealand Ministry of 
Health, 2002). Currently, there is no reported data on the effect of these factors on the 
outcomes for patients treated with dabigatran etexilate. 
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1.11 Overall study aims 
The main overall goal of this research was to form a better understanding of dabigatran 
etexilate prescribing and monitoring in New Zealand. Chapters two to five investigate 
the following thesis aims in more detail to gain a more complete understanding of 
dabigatran etexilate prescribing and monitoring in New Zealand. The research hypothesis 
for this thesis was that current utilisation of dabigatran etexilate places some individuals 
at greater risk of adverse outcomes. The thesis aims were designed to test this hypothesis 
and confirm if these factors influence outcomes in those prescribed dabigatran etexilate. 
1.11.1 Thesis aims 
This thesis aims to investigate aspects of dabigatran etexilate utilisation in New Zealand. 
This encompasses the broad goal of increasing understanding and awareness of 
dabigatran etexilate use and outcomes in New , as well as a 
better understanding of prescribing habits and monitoring. 
Specific aims: 
Chapter two: 
To describe current use, effectiveness and safety of treatment with dabigatran 
etexilate in the New Zealand population. 
Chapter three: 
To investigate the difference between different estimators of renal function and 
the risk of adverse outcomes for patients with atrial fibrillation when these 
different estimators are used for dose selection of dosing dabigatran etexilate. 




To investigate the relationship between dabigatran etexilate exposure and adverse 
response in real-world patients. 
Chapter five: 
To investigate if clinically appropriate renal function testing recommendations 
were being undertaken in New Zealand primary care for atrial fibrillation patients 
prescribed dabigatran etexilate. 
  







Paper ONE Deprivation and inequalities lead to worse outcomes 
with dabigatran etexilate.
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2 Paper ONE Deprivation and inequalities lead to worse 
outcomes with dabigatran etexilate 
2.1 Preface 
The following chapter contains a publishe Deprivation and 
inequalities lead to worse outcomes with dabigatran etexilate
published in the Journal of Primary Health Care in 2018. Journal of Primary Health Care 
2018; 10: 303-311. doi: 10.1071/HC17081 (B. H. Simpson, Reith, Medlicott, & Smith, 
2018). See Appendix 3. 
As established in chapter one, dabigatran etexilate is the most commonly used oral 
anticoagulant used in New Zealand. However, while there is some international data on 
the usage of dabigatran etexilate New Zealand specific data is lacking. As a result, there 
is limited New Zealand specific knowledge relating to prescribing trends, adverse 
outcomes and the effects of patient demographics for those prescribed dabigatran 
etexilate. 
Therefore, the aim of this chapter/study was to use a population study to describe current 
use, effectiveness and safety of treatment with dabigatran etexilate in the New Zealand 
population. 
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2.2 Deprivation and inequalities lead to worse outcomes with 
dabigatran etexilate. 
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1University of Otago New Zealand's National School of Pharmacy Dunedin, NZ 
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Introduction: Dabigatran etexilate now accounts for 51% of the patients receiving oral 
anticoagulation in New Zealand. Its prescribing trends in relation to patient outcomes 
are, however, largely unknown for New Zealand patients. 
Aim: To describe patient characteristics, effectiveness and safety of treatment with 
dabigatran etexilate in the New Zealand population. 
Methods: This retrospective cohort study used administrative health data from New 
Zealand for patients dispensed dabigatran etexilate between 1 July 2011 and 31 
December 2015. Adverse event (haemorrhage) or treatment failure (thromboembolism 
or cerebrovascular accident) data were extracted and linked to patient specific 
demographic data. Baseline patient characteristics were analysed with descriptive 
statistics to examine trends in dabigatran etexilate prescribing. Raw and adjusted hazard 
ratios including covariates were derived using Cox proportional hazard models. 
Results: 52413 patients were dispensed dabigatran etexilate. Multivariate analysis 
indicated the risk of haemorrhagic events were significantly increased by ethnicities of 
2.86)) and Pacific Peoples (HR; 95%CI: 2.20 (1.49
3.24)), age greater than 80 years (HR; 95%CI: 1.25 (1.08 1.43)) and more deprived 
quintile ratings of Q4 (HR; 95%CI: 1.24 (1.08 1.43)) and Q5 (HR; 95%CI: 1.30 (1.12
1.50)). There was an increased risk of thromboembolism and cerebrovascular accident 
for those greater than 80 years of age (HR; 95%CI: 1.79 (1.49 2.15)). 
Discussion: Demographic factors are associated with adverse outcomes in patients 
treated with dabigatran etexilate. Targeted strategies are needed to prescribe more 
appropriately in these populations. 




Dabigatran etexilate, a direct thrombin inhibitor, has been available in New Zealand by 
full subsidy since July 2011. Following its introduction it has been rapidly adopted with 
51% of patients receiving oral anticoagulation now being treated with dabigatran 
etexilate (Best Practice Advocacy Centre (bpacnz), 2017a). This rapid adoption can be 
partly attributed to dabigatran having very few interactions with other medications and 
food along with the minimal requirement for routine laboratory monitoring (Schulman, 
2014). 
Treatment with dabigatran etexilate is complicated by limited knowledge of its real-
world safety and efficacy (Alexander et al., 2011) such as its use for the prevention of 
thromboembolic events in different patient populations. Depending on clinical risk 
factors the dose of dabigatran etexilate can be affected by a number of patient variables. 
Currently the New Zealand approved medicines datasheet recommends a dose of 150mg 
twice daily for all indications except for the treatment of non-valvular atrial fibrillation 
patients over the age of 75 years (Boehringer Ingelheim (N.Z.) Limited, 2017). For those 
between the ages of 75-80 years the dose maybe reduced to 110 mg twice daily if the 
perceived thromboembolic risk is low while the haemorrhage risk is high (Boehringer 
Ingelheim (N.Z.) Limited, 2017). For any patient over the age of 80 years the 
recommended dose is 110 mg twice daily (Boehringer Ingelheim (N.Z.) Limited, 2017).  
Whilst there are some international data on the use of dabigatran available (European 
Medicines Agency, 2011; Loo et al., 2017; Weitz et al., 2015; Yao et al., 2016), New 
Zealand prescribing trends for dabigatran etexilate are largely unknown. There is limited 
data relating to the demographics and adverse outcomes such as haemorrhage or 
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thromboembolism embolism associated in those patients prescribed dabigatran etexilate 
in New Zealand (Metcalfe et al., 2012). Also, there are no reported data investigating 
how demographics affect patient outcomes at regional or national levels. 
The aim of this population study was to describe current use, effectiveness and safety of 
treatment with dabigatran etexilate in the New Zealand population. 
2.2.3 Methods 
2.2.3.1 Identification of study cohort 
A retrospective cohort study using administrative health data from New Zealand was 
conducted. The study population included all patients aged 18 years or older who had at 
least one dispensing of dabigatran etexilate during the study period between 1 July 2011 
and 31 December 2015. The information from the different datasets were linked using 
patients encrypted National Health Index number (NHI; a life-long unique identifier for 
all interactions with the health system) to ensure patient anonymity. Ethical approval was 
obtained from the University of Otago Ethics Committee (Reference number HD15/054) 
(See Appendix 1 & 2). 
2.2.3.2 Patient Information 
Patient data were extracted from the Pharmaceutical Collection (New Zealand Ministry 
of Health, 2016b) (PC) which contains prescription details about community 
pharmaceutical dispensing claims for all nationally funded medicines. It also provides 
information on gender, date of birth, age, ethnicity, deprivation index score, geographic 
location via District Health Board (DHB), prescriber type, frequency and quantity 
dispensed. Patients were categorised into age groupings of under 65 years, 65-74 years, 
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75-80 years and over 80 years to align to both regulatory and commonly used clinical 
stratifications (Committee for Human Medicinal Products (CHMP), 2007; U.S. 
Department of Health and Human Services Food and Drug Administration, 2012). 
Continuous dabigatran etexilate use was defined as one or more prescriptions recorded 
in the PC with less than 120 days between dispensing (prescriptions in New Zealand for 
dabigatran etexilate typically provide 90 days supply which are provided in 30 day 
amounts). When 120 days or more elapsed between dabigatran etexilate prescriptions, a 
participant was recorded as having intermittent treatment with dabigatran etexilate. 
2.2.3.3 Patient Outcomes 
The outcomes of interest were any admission to hospital for a possible adverse event of  
haemorrhage, or treatment failure of thromboembolism or cerebrovascular accident 
(CVA) and were extracted from the National Minimum Dataset (NMDS) (2015). 
Unspecified CVA were also included for any diagnosis without a classification of 
haemorrhagic or thrombotic. The NMDS is the national record of all public and private 
hospital discharge information, including coded clinical data for admissions greater than 
four hours. The recorded diagnoses are coded using the International Classification of 
Diseases and Related Health Problems Tenth Revision, Australian Modification (ICD-
10-AM) (National Centre for  Classification in Health, 2008). Participants were followed 
from their first dispensing of dabigatran etexilate until the date of hospitalisation, 
cessation of dabigatran etexilate treatment or study end. 
2.2.3.4 Statistical Analyses 
Baseline patient characteristics were analysed with descriptive statistics to examine 
trends in dabigatran etexilate prescribing. Continuous variables were tested for normal 
distribution by the skewness and kurtosis test. Normally distributed data are presented as 
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the mean (standard deviation) and non-normally distributed data as the median 
(interquartile range).  
Differences between groups were analysed using t-tests, Kruskal Wallis tests and 
pairwise correlations, as appropriate. Hazard ratios (95% confidence intervals (95% CI)), 
for adverse patient outcomes, comparing different covariates were derived from Cox 
proportional hazard models. An adjusted hazard ratio (95% CI) was obtained using 
bidirectional backwards then forwards stepwise Cox proportional hazard models 
regression. The variables considered were geographic location, ethnicity, gender, age, 
deprivation and dispensed formulation. The level of significance adopted for the 
variables was p < 0.05 for inclusion and p < 0.01 for re-inclusion. Outcomes with p < 
0.05 were considered statistically significant. 
Statistical analyses were performed using Stata/IC (v.14.2, StatCorpLP, Texas, USA). 
2.2.4 Results 
2.2.4.1 Patient demographics 
Between 1 July 2011 and 31 December 2015, a total of 52413 patients were initiated on 
dabigatran etexilate treatment. Of these patients, 5321 (10.2%) had intermittent treatment 
and 31040 (59.2%) were male. The median age was 72 years (63-79 years) and the 
majority of patients 38020 (72.5%) were aged 65 years or over.  
Table 8 summarises the ethnic distribution of patients prescribed dabigatran etexilate 
with 
disproportionately represented in the more deprived quintiles (Q4 and Q5) while New 
Zealand Europeans were represented more in the less deprived quintiles (Q1, Q2, and 
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Q3). Asian, Middle Eastern, Latin American and African (MELAA) and other ethnicities 
were more evenly distributed across all the quintiles. A Kruskal-Wallis test showed that 
there was a statistically significant difference in deprivation index score between the 
different geographic locations 2 (20) = 2685.4, p = 0.001. Geographic locations with 
higher deprivation index score had greater use of dabigatran etexilate per 1000 of 
population (p = 0.004). A summary of the demographic characteristics of the patients, 
separated by geographic location is presented in Table 9. 
Table 8 Ethnic distribution of patients dispensed dabigatran etexilate 
Ethnicity (n) 
Least deprived    Most deprived 
Q1 Q2 Q3 Q4 Q5 
NZ European (41,044) 6078 (22.3) 6062 (22.3) 6065 (22.3) 5319 (19.6) 3677 (13.5) 
 (6158) 208 (4.8) 333 (7.7) 578 (13.3) 1037 (23.8) 2196 (50.5) 
Pacific Peoples (1654) 59 (5.2) 100 (8.8) 120 (10.6) 239 (21) 618 (54.4) 
Asian (1152) 185 (24.5) 145 (19.2) 138 (18.3) 172 (22.8) 115 (15.2) 
MELAA (157) 20 (20.2) 27 (27.3) 16 (16.2) 17 (17.2) 19 (19.2) 
Other (2248) 384 (25.8) 362 (24.3) 313 (21.0) 240 (16.1) 188 (12.6) 
Total (52,413)  6934 (19.8) 7029 (20.1) 7230 (20.6) 7024 (20.1) 6813 (19.4) 
Data are presented as n (%). NZ (New Zealand); MELAA (Middle Eastern/Latin 
American/African). 
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2.2.4.2 Prescriber type 
Primary health care physicians initiated dabigatran etexilate for 31384 (59.9%) patients with 
this increasing to 42237 (80.6%) for ongoing treatment. Secondary health care physicians 
initiated 7316 (14.0%) patients with this decreasing to 3692 (7.0%) for ongoing treatment. 
Other health care providers initiated 13713 (26.2%) and provided ongoing treatment for 6482 
(12.4%) patients. 
2.2.4.3 Adverse events requiring hospitalisation 
The median follow-up time for participants was 240 days (IQR: 90 690 days). Approximately 
1 in 10 patients required hospitalisation due to an adverse event possibly related to dabigatran 
etexilate; there were 2887 (5.5%) haemorrhagic events, 1419 (2.7%) thromboembolic/CVA 
events and 1170 (2.2%) unspecified CVA. Stratification of adverse events by geographic 
location are presented in Table 9. 
The median time to a haemorrhagic event was 240 days (IQR: 65 630 days), 
thromboembolic/CVA event was 267 days (IQR: 78-613 days) and an unspecified CVA was 
280.5 days (IQR: 81-640 days). 
The median age for a haemorrhagic event was 76 years (IQR: 68-82 years), 
thromboembolism/CVA 78 years (IQR: 70-83 years) and an unspecified CVA was 78 years 
(IQR: 69-83 years). 
Multivariate analysis indicated that the variables significantly associated with an increase in 
haemorrhagic events were: 
Peoples, and New Zealand European, deprivation quintiles 4 and 5 and receiving the 150 mg 
formulation (Table 10). The variables significantly associated with an increase in 
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thromboembolism/CVA were; geographic location, age over 80 years and deprivation quintile 
5 (Table 10). The variables significantly associated with an increase in unspecified CVA were 
geographic location, age 75-80 years, age over 80 years, fic 




Table 10 Estimated hazard ratio (HR) and 95% confidence interval (95%CI) of haemorrhage, 
thromboembolism/CVA or unspecified CVA, by general patient demographics (n = 52,413) 





regression Simple regression 
Multiple 
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CVA (cerebrovascular accident); MELAA (Middle Eastern/Latin American/African); DHB (District Health Board). 
* Statistically significant 
 Not included in final model 
 




This study aimed to produce a more complete picture of the current use, effectiveness 
and safety of treatment with dabigatran etexilate in the New Zealand population. The 
study highlights that dabigatran etexilate is mainly prescribed in primary care to the 
elderly and areas with a higher deprivation score have significantly higher usage. 
2.2.5.1 Adverse events 
The rate of haemorrhagic adverse events in the current study of 5.5% is lower than that 
reported in the New Zealand Medicines Datasheet (Boehringer Ingelheim (N.Z.) 
Limited, 2017). Conversely there is a higher rate of adverse outcomes of 
thromboembolism/CVA with a rate of 2.7% in the current study compared with the New 
Zealand Medicines Datasheet (Boehringer Ingelheim (N.Z.) Limited, 2017). The effects 
of demographic factors on dabigatran etexilate treatment outcomes has not been 
previously reported for New Zealand patients. This study showed that living in certain 
geographical locations, subjection to higher deprivation, being over 80 years of age, or 
identifying as M ori or Pacific Peoples were all linked to an increased risk for adverse 
outcomes. While previous studies have shown a relationship between geographic related 
deprivation and poor health outcomes in general for New Zealanders (Abas et al., 2006; 
Atkinson et al., 2014; Barnett et al., 2003; Exeter et al., 2017) none have investigated this 
in relation to dabigatran etexilate treatment. This study specifically showed that those 
patients who are more deprived are more likely to experience haemorrhagic events that 
can be attributed dabigatran etexilate. This is consistent with the findings of a New 
Zealand national healt
the most deprived areas of New Zealand generally report greater unmet need than 
others (New Zealand Ministry of Health, 2016a). To address this issue additional 
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resources/strategies need to be targeted at these populations during treatment initiation 
 
The time to either adverse event or treatment failure occurs predominately in the first 2 
years of treatment. A median time of 120 days (IQR: 30-340 days) to haemorrhagic event 
has been previously reported only for gastrointestinal haemorrhage (Abraham et al.). The 
current study combined all forms of haemorrhagic events and showed that the majority 
of these occur in the first 2 years of treatment. This indicates the importance of adhering 
to recommended patient monitoring at clinically appropriate timeframes. For example, it 
has been reported that patients with atrial fibrillation receiving oral anticoagulation 
exhibit a decline in renal function over time indicating the need for renal function 
monitoring at regular intervals (Böhm et al., 2015). There are varying reports indicating 
different levels of compliance to recommended monitoring timeframes (Thorne et al., 
2015) making it important to increase the awareness of clinicians and patients of 
appropriate clinical monitoring. This could involve development of consistent education 
programmes, such as national continuing medical education modules. 
The limitations of this study include the NMDS only capturing patient data for those who 
require hospitalisation for a duration of more than 4 hours. Therefore, outcomes of 
interest that did not meet this criteria, for example a haemorrhage or CVA that resulted 
in death, would not be included in the dataset resulting in possible under estimations. 
Also, there can be errors in the clinical codes entered in the NMDS resulting in possible 
inclusion or exclusion of the clinical outcomes of interest. As comorbidities vary between 
ethnicities and as their interaction with dabigatran etexilate treatment is not accounted 
for in this study there is possible bias in outcome profiles. For example, 
higher prevalence of diabetes and this may attribute to CVA at younger ages (Wong et 
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al., 2016).  With no diagnostic information contained in the NMDS it was therefore not 
possible to investigate disease specific dose regimens by indication. The main strength 
of this study is the inclusion of a large national cohort of patients, with sufficient sample 
size to provide adequate information about the effects of demographics on dabigatran 
etexilate outcomes for an entire population. 
Pacific Peoples ethnicity are at greater risk of harm compared with other ethnicities. 
2.2.6 Conclusion 
We have provided new evidence that demographic factors can directly affect outcomes 
for those treated with dabigatran etexilate and real-world evidence for when these events 
occur. Improvement of outcomes could be achieved by increased vigilance of clinical 
monitoring especially in the the elderly and those 
who are more deprived. 
  










Paper TWO Choice of renal function estimator influences 
adverse outcomes with dabigatran etexilate in patients with atrial 
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3 Paper TWO Choice of renal function estimator influences 




function estimator influences adverse outcomes with dabigatran etexilate in patients with 
8, 
02 (04), e420-e427, doi: 10.1055/s-0038-1676356 (B. H. Simpson, Reith, Medlicott, & 
Smith, 2018). See Appendix 4. 
The importance of using the correct estimati
highlighted in chapter one. Using different estimators of renal function can result in 
different doses of dabigatran etexilate being prescribed. A relationship between 
inappropriate dosing of dabigatran etexilate and adverse patient outcomes has previously 
been described in the literature. 
Currently, there are no reported studies investigating how the use of different renal 
function estimators affects patient outcomes for individuals with atrial fibrillation who 
are prescribed dabigatran etexilate. 
Therefore, the aim of this chapter/study was to investigate the difference between 
different estimators of renal function and the risk of adverse outcomes (haemorrhage or 
thromboembolism) for patients with atrial fibrillation when these different estimators are 
used for dose selection of dosing dabigatran etexilate.  
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3.2.1 Abstract 
Background: Clinical significance of dosing dabigatran with different estimates of renal 
function for treatment of atrial fibrillation (AF) is unknown. Renal function is routinely 
estimated by the chronic kidney disease epidemiology initiative equation (CKD-EPI) and 
used to guide dosing. The aim of this study was to investigate the risk of adverse 
outcomes for patients with AF when different estimators of renal function are used. 
Material and Methods: AF patient data were extracted from national administrative 
databases. Renal function was estimated using Cockcroft-Gault, CKD-EPI and CKD-EPI 
adjusted for BSA (CKD-EPI-BSA). Outcomes of cerebrovascular accident (CVA), 
systemic embolism (SE) and haemorrhage were extracted. 
Results: 2425 patients were identified, of which there were hospitalisations for 138 
(5.7%) haemorrhagic events, 45 (1.9%) CVA/SE and 33 (1.4%) unspecified CVA. The 
level of agreement between Cockcroft-Gault with CKD-EPI and CKD-EPI-BSA yielded 
a weighted Kappa statistic of 0.47 and 0.71, respectively. CKD-EPI and CKD-EPI-BSA 
significantly overestimated renal function in elderly patients resulting in higher 
recommended doses compared with Cockcroft-Gault. The hazard ratio for a 
haemorrhagic event was 2.32 (95%CI, 1.22-4.42; p=0.01) when a high dose was given 
compared to normal dose, based on Cockcroft-Gault. 
Conclusions: Both CKD-EPI and CKD-EPI-BSA equations significantly overestimated 
renal function in the elderly population compared with the Cockcroft-Gault equation. 
This may lead to dose selection errors for dabigatran, particularly for those with severe 
impairment, increasing the risk of adverse outcome. Hence, CKD-EPI and CKD-EPI-
BSA equations should not be substituted for the Cockcroft-Gault equation in the elderly 
for the purpose of renal dosage adjustments. 




Previous studies have shown that using different estimators of renal function can result 
in different doses of dabigatran etexilate, a non vitamin K antagonist oral anticoagulant 
(NOAC), being prescribed to patients (Dowling et al., 2013; Hellden et al., 2013; Hudson 
et al., 2014; MacCallum et al., 2013; Manzano-Fernández et al., 2015; Pérez Cabeza et 
al., 2018). Approximately 80% of dabigatran etexilate is eliminated by renal 
excretion (Ezekowitz et al., 2009) making it important to ensure renal function is 
estimated appropriately when selecting individual doses. It has also been reported that 
there is a relationship between clinically inappropriate dosing of NOACs (including 
dabigatran etexilate) and adverse clinical outcomes (Steinberg et al., 2016; Yao et al., 
2017). Currently there are no reported data showing how the use of different renal 
function estimators affects patient outcomes for individuals with atrial fibrillation (AF) 
who receive treatment with dabigatran etexilate. 
The Cockcroft-Gault equation (Cockcroft et al., 1976) has long been used in clinical care, 
since its development in 1976, to evaluate renal function by estimating creatinine 
clearance (CrCl). More recently alternative methods have been adopted such as the 
original modification of diet in renal disease (MDRD) equation, the abbreviated MDRD 
equation 4 (MDRD-4) and the chronic kidney disease epidemiology initiative (Levey et 
al., 2009) (CKD-EPI). These latter equations provide estimates of glomerular filtration 
rate (eGFR) normalised to a body surface area (BSA) of ml/min/1.73m2. It has been 
reported that CKD-EPI gives the best estimation of glomerular filtration rate of these 
three equations (Michels et al., 2010). However, despite this the recommended guidance 
for evaluation of pharmacokinetics of medicines in patients with decreased renal function 
from the United States Food and Drug Administration (FDA) (U.S. Department of Health 
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and Human Services, 1998) and European Medicines Agency (EMA) (European 
Medicines Agency, 2015) does not specify one particular method of estimation. This 
allows for worldwide inconsistency in dosage recommendations in patients with 
decreased renal function. 
In New Zealand, CKD-EPI is the renal function estimate of choice for clinical care and 
is now routinely reported in patient notes following plasma creatinine blood 
tests (Johnson et al., 2012). It is probable that CKD-EPI is being used to guide dabigatran 
etexilate dosing (Howey et al., 2013) despite clinical guidance from the sponsor and 
international scientific societies recommending the Cockcroft-Gault 
equation (Boehringer Ingelheim (N.Z.) Limited, 2017; January et al., 2014; Steffel et al., 
2018). When eGFR is used by clinicians to guide dabigatran etexilate dosing there is a 
need to adjust the result for the individ
at the extremes of body size (Jones, 2011). Failing to adjust for BSA has the potential to 
lead to incorrect estimation of renal function and result in inappropriate dose selection. 
Currently there is no guidance to adjust for those patients who have a BSA not close to 
1.73m2. Furthermore, the presence of different methods of estimating renal function has 
created some confusion for clinicians as to the best approach in clinical practice (Chin, 
Wright, & Florkowski, 2014; Jones, 2011). 
The aim of the present study was to investigate the difference between different 
estimators of renal function and the risk of adverse outcomes (haemorrhage or 
thromboembolism) for patients with AF when these different estimators are used for dose 
selection of dosing dabigatran etexilate. To achieve this, we have used a high-quality 
observational dataset encompassing several high volume centres to address this issue. 




3.2.3.1 Identification of study cohort 
This was a retrospective cohort study using administrative health data from New Zealand. 
The databases accessed were the Best Practice Intelligence (BPI) database operated by 
Best Practice Advocacy Centre Clinical Solutions, New Zealand (Best Practice Inc) and 
the New Zealand Ministry of Health Pharmaceutical Collection (New Zealand Ministry 
of Health, 2016b) (PC). The BPI database is a secure, internet based, reporting tool that 
uses data downloaded from the enrolled general practice patient electronic health record 
(EHR) and covers approximately 20% of the New Zealand population. The PC contains 
prescription details about pharmaceutical dispensing claims for dabigatran etexilate 
along with other prescribed medicines as well as information on gender, date of birth, 
age, ethnicity, frequency and quantity dispensed for all of the New Zealand population. 
The study population included patients; with a diagnosis of AF by the general practitioner 
(READ codes G573, G5730, G5731, G5732, G573z), aged 18 years or older, had at least 
one dispensing of dabigatran etexilate during the study period between 1 July 2011 (when 
dabigatran etexilate became available in New Zealand) and 31 December 2015, serum 
creatinine measurements within 60 days before or 30 days after their first dispensing of 
dabigatran etexilate, at least one height measurement, and bodyweight measurements 
within 1 year before or after their first dispensing of dabigatran etexilate. If multiple 
serum creatinine or bodyweight measurements were recorded, the measurement closest 
to the initiation of dabigatran etexilate initiation was used. Weight measurements more 
than five standard deviations from the mean were considered to be data entry errors and 
were excluded. If multiple height measurements were recorded for an individual patient, 
the mean was calculated, with any measurement more than two standard deviations from 
the mean height being excluded. Any patients who had a height measurement (either as 
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a single or average measurement) that was more than five standard deviations from the 
cohort mean were excluded. Where an alternative weight or height measurement was not 
recorded the patient was excluded from the cohort. The information from different 
datasets were linked u ncrypted National Health Index number (NHI; 
a life-long unique identifier for all interactions with the New Zealand health system) to 
ensure patient anonymity. Ethical approval was obtained from the University of Otago, 
New Zealand Ethics Committee (Reference: HD15/054) (See Appendix 1 & 2). 
3.2.3.2 Patient covariates 
Dispensed medications, patient demographic and covariate data were extracted from the 
PC and BPI databases for patients who meet the inclusion criteria. Patients were 
categorised into age groupings of under 65 years, 65-74 years, 75-79 years and over 80 
years to align to both regulatory and the categories used by the sponsor to guide 
dosing (Boehringer Ingelheim (N.Z.) Limited, 2017; Committee for Human Medicinal 
Products (CHMP), 2007). The treatment period with dabigatran etexilate was determined 
by the number of days supplied for each series of continuous treatment. Continuous 
dabigatran etexilate use was defined as one or more dispensings recorded in the PC with 
less than 120 days between dispensing (prescriptions in New Zealand for dabigatran 
etexilate typically supply 90 days which are dispensed in 30 day amounts). When 120 
days or more elapsed between dabigatran etexilate prescriptions, a patient was considered 
to have ceased dabigatran etexilate treatment. If the patient restarted dabigatran etexilate 
treatment after 120 days or more had elapsed they were considered as a new patient in 
the study. 
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Estimation of renal function Baseline renal function was estimated via three different 
methods using the serum creatinine measurement closest to the first dispensing of 
dabigatran etexilate: 




CrCl = creatinine clearance, 
age = age in years, 
weight = weight in kg, 
SCr = serum creatinine (expressed in mg/dL). 
 
Equation 1: Cockcroft-Gault 
(2) Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) (Levey et al., 
2009) equation using Equation 2: 
 
Where: 
eGFR = estimated glomerular filtration rate, 
 
 
 1,  
 
age = patient age in years, 
SCr = serum creatinine (expressed in mg/dL). 
 
Equation 2: CKD-EPI 
(3) Chronic Kidney Disease Epidemiology Collaboration adjusted for BSA (CKD-EPI-
BSA) equation using Equation 5: 




eGFR = estimated glomerular filtration rate, 
 
 for femal  
 
 
age = patient age in years, 
SCr = serum creatinine (expressed in mg/dL), 
BSA= individuals body surface area, 
(kg))/3600)]. 
 
Equation 5 CKD-EPI-BSA 
 
Patients were classified per equation according to the renal impairment dose stratification 
for AF according to the sponsor s medicines data sheet (Boehringer Ingelheim (N.Z.) 
Limited, 2017). These were: no dose adjustment required (i.e. 300 mg 
daily); ( dose reduction to 220mg daily; (3) <30 
ml/min use contra-indicated. 
3.2.3.3 Patient Outcomes 
The outcomes of interest were any admission to hospital for haemorrhage or 
thromboembolism (Supplementary Table 1) and were extracted from the New Zealand 
Ministry of Health National Minimum Dataset (NMDS) (2015). The NMDS is the 
national record of all public and private hospital discharge information, including coded 
clinical data for admissions greater than four hours for all of the New Zealand population. 
The recorded diagnoses are coded using the International Classification of Diseases and 
Related Health Problems Tenth Revision, Australian Modification (ICD-10-
AM) (National Centre for  Classification in Health, 2008). Patients were followed from 
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their first dispensing of dabigatran etexilate until the date of hospitalisation, cessation of 
dabigatran etexilate treatment or study end. 
3.2.3.4 Statistical analyses 
Statistical analyses were performed using Stata/IC (Version 14.2, StataCorpLP, TX, 
USA). Continuous variables were tested for normal distribution by the skewness and 
kurtosis test. Normally distributed data are presented as the mean ± standard deviation 
and non-normally distributed data as the median (interquartile range) with between group 
comparisons tested with paired-samples t-test. Categorical variables were expressed as 
percentages and compared by Chi-square tests. Analysis of variance (ANOVA) and the 
Wilcoxon signed-ranks test were used to compare the difference in renal clearance in 
of agreement between the equations. Differences in the number of patients categorised 
in the three dose stratifications based on CrCl (as calculated using Cockcroft-Gault) 
compared to eGFR (as calculated using either CKD-EPI or CKD-EPI-BSA) were 
compared using the Chi-Square t. Discordance rates of dosing were 
calculated as the percentage of patients with a different dose than that determined by the 
Cockcroft-Gault equation divided by the total number of patients multiplied by 100. 
Hazard ratios (95% confidence intervals (CI)) comparing different estimates of renal 
function and the actual dose of dabigatran etexilate dispensed (i.e. correct, low or high 
doses) were derived from Cox proportional hazard models. Results were considered 
statistically significant if p<0.05. 
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3.2.4 Results 
3.2.4.1 Patient characteristics 
There were 2425 patients identified in the databases that had been dispensed dabigatran 
etexilate with a diagnosis of AF, aged 18 years or more, one or more serum creatinine, 
bodyweight and height measurements recorded. The median age of patients in this cohort 
was 72 years (IQR: 65-78 years) and 1417 (58.4%) were male. The median bodyweight 
was 85 kg (IQR: 73-100 kg), median height was 1.7 m (IQR: 1.6-1.8 m), and median 
BSA was 2.0 m2 (IQR: 1.8-2.2 m2). 
3.2.4.2 Baseline renal function estimation 
Patient renal function decreased significantly (p<0.05) in relation to increasing age for 
the three different estimations (Figure 10). Comparing the level of agreement between 
the equations yielded a weighted Kappa coefficient of 0.47 (p<0.05) between Cockcroft-
Gault and CKD-EPI and 0.71 (p<0.05) between Cockcroft-Gault and CKD-EPI-BSA. 
Comparisons at the specified age stratifications showed similar levels of agreement with 
fair agreement for CKD-EPI and moderate agreement for CKD-EPI-BSA (Table 11). 
When comparing the Cockcroft-Gault equation to the CKD-EPI and CKD-EPI-BSA 
equations across all age ranges, the Cockcroft-Gault equation produced a significantly 
higher estimated median renal function, 74.9 ml/min (IQR: 55.8 99.1 ml/min) than 
CKD-EPI, 67.6 ml/min/1.73m2 (IQR: 55.4 79.8 ml/min/1.73m2); (p<0.05). When 
comparing Cockcroft-Gault to the CKD-EPI equation at the specified age stratifications 
CKD-EPI significantly underestimated until 80 years of age when it then significantly 
overestimated (Table 11). When comparing Cockcroft-Gault to the CKD-EPI-BSA 
equation the Cockcroft-Gault equation produced non-significant lower estimated median 
renal function than CKD-EPI-BSA, 77.4 ml/min (IQR: 60.7 95.4 ml/min); (p=0.968). 
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When comparing Cockcroft-Gault to CKD-EPI-BSA equation over the specified age 
stratifications, CKD-EPI-BSA gave significantly lower estimates until 75 years of age 
when it then significantly overestimated (Table 11). 
 
Figure 10 Adjusted predictions (ANOVA) of baseline renal function with 95% CI for 
patients dispensed dabigatran etexilate by the Cockcroft-Gault equation, CKD-EPI 













































































































































































































































































































































































































































































































































































































Both CKD-EPI and CKD-EPI-BSA provided biased estimates of renal function when 
compared to Cockcroft-Gault, with the bias being smaller for CKD-EPI-BSA (Figure 11). The 
mean within-patient differences relative to the Cockcroft-Gault equation were 14.8 ml/min 
(95% CI; 13.6 15.9) for CKD-EPI (p<0.05) and 2.6 ml/min (95% CI; 1.9 3.2) for CKD-EPI-
BSA (p<0.05). The limits of agreement of CKD-EPI and CKD-EPI-BSA with the Cockcroft-
Gault equation were -42.5 to 72.0 ml/min for CKD-epi and -31.2 to 36.3 ml/min for CKD-EPI-
BSA. 
 
Figure 11 Bland and Altman plots showing the within person differences between the 
estimated CrCl obtained by using the Cockcroft-Gault equation and eGFR obtained by using 
the CKD-EPI equation (A) and CKD-epi adjusted for body surface area (B). The solid line 
indicates the mean difference and the dashed line indicates limits of agreement. Chronic 
Disease Epidemiology Collaboration; CKD-EPI-BSA, Chronic Disease Epidemiology 
Collaboration adjusted for body surface area. 
Table 12 shows the renal dose stratification of patients according to the different renal function 
estimations. There were significant differences in all the renal dose stratifications of <30 
ml/min and 30-49 ml/min produced by CKD-EPI and CKD-EPI-BSA compared to Cockcroft-
Gault (p < 
significant difference for CKD-EPI compared to Cockcroft-Gault (p <0 .05) while there was a 




















































































































































































































































































































































































































Discordance rates in the recommended doses determined using the CKD-EPI or CKD-EPI-
BSA equations compared with Cockcroft-Gault are shown in Table 13. For both estimators, 
disagreement in dose across all age ranges was because of an overall higher dose recommended 
by CKD-EPI and CKD-EPI-BSA compared with the Cockcroft-Gault dose. When discordance 
rates for dabigatran etexilate were evaluated by age grouping, the discordance rate increased 
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3.2.4.3 Adverse events requiring hospitalisation 
Approximately 9% of patients required hospitalisation due to an adverse event possibly 
related to dabigatran etexilate; there were 138 (5.7%) haemorrhagic events, 45 (1.9%) 
thromboembolic/CVA events and 33 (1.4%) unspecified CVA. The median follow up for 
patients was 1.4 years (IQR: 0.4 2.5 years). For adverse events, the median time to a 
haemorrhagic event was 1.0 year (IQR: 0.3 1.9 years), cerebral vascular incident or 
systemic embolism was 0.9 years (IQR: 0.4 1.8 years) and an unspecified cerebral 
vascular incident was 0.9 years (IQR: 0.2 1.6 years). 
While all methods showed that they were protective of a haemorrhage at the correct dose 
only the Cockcroft-Gault estimation significantly indicated that those with a high dose 
dispensed were more likely to have a haemorrhage (Table 14). Hence, if the Cockcroft-
Gault equation is not used to guide dosing, there is an associated increased risk of 
haemorrhagic event. However, dosing by CKD-EPI or CKD-EPI-BSA did not provide 
guidance that would enable dose modification to prevent these events.  
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Table 14 Estimated hazard ratio (HR) and 95% confidence interval (95%CI) of 
haemorrhage, thromboembolism/CVA or unspecified CVA, by actual dose dispensed 
compared to renal function estimator method 
Haemorrhage Thromboembolism/CVA Unspecified CVA 
HR (95%CI; p-value) HR (95%CI; p-value) HR (95%CI; p-value) 
Cockcroft-Gault    
Correct Dose (n=1503) 0.57* (0.41 0.79; 0.001) 0.57 (0.32 1.02; 0.057) 0.71 (0.36 1.42; 0.335) 
High Dose (n=85) 2.32* (1.22 4.42; 0.01) - 0.93 (0.13 6.84; 0.947) 




Correct Dose (n=1463) 0.66* (0.47 0.92; 0.014) 0.6 (0.34 1.08; 0.09) 0.67 (0.34 1.33; 0.251) 
High Dose (n=84) 1.06 (0.43 2.58; 0.904) - - 




Correct Dose (n=1416) 0.66* (0.48 0.93; 0.016) 0.56 (0.31 1; 0.052) 0.51 (0.26 1.02; 0.058) 
High Dose (n=40) 1.17 (0.37 3.66; 0.792) - - 
Low Dose (n=969) 1.49* (1.07 2.08; 0.019) 1.94* (1.08 3.5; 0.027) 2.11* (1.06 4.2; 0.035) 
* Statistically significant 
- not included in the model due to insufficient numbers 
CKD-EPI: chronic kidney disease epidemiology initiative equation 
CKD-EPI-BSA: chronic kidney disease epidemiology initiative equation adjusted for body surface area 
HR: Hazard Ratio 
CVA: Cerebrovascular accident 
  




This study demonstrates that substituting renal function estimated by CrCl (Cockcroft-
Gault) with eGFR (CKD-EPI or CKD-EPI-BSA) can also negatively influence adverse 
outcomes with dabigatran etexilate for some patients, with elderly patients having the 
highest risk. This is likely to be the result of higher doses of dabigatran etexilate being 
prescribed for patients whose renal function is near the limits of the recommended dose 
stratifications.  
Using individual patients  data, we determined doses of dabigatran etexilate if the 
prescriber used the different methods to estimate renal function. We then compared the 
difference in the dose they would receive based on the CKD-EPI and CKD-EPI-BSA 
equations with the Cockcroft-Gault equation, as this is the method used for dose 
stratification in the  summary of product characteristics, to determine dose 
discordance. The greatest dose discordance compared to the Cockcroft-Gault equation 
was observed for: (1) patients over 75 years of age for CKD-EPI (received a 
supratherapeutic dose) and (2) patients over 80 years of age for CKD-EPI-BSA (received 
a supratherapeutic dose). 
Hence, it appears the choice of renal function estimator is important for individuals over 
75 years of age. It is at these points that patients with a CrCl below the recommended 
dosing stratifications (i.e. 50ml/min and 30ml/min) are likely to be estimated higher with 
eGFR and therefore receive a clinically inappropriate high dose. This indicates that the 
CKD-EPI and CKD-EPI-BSA equations should not be used as an alternative for 
Cockcroft-Gault equation when estimating renal function to guide dabigatran etexilate 
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dosing in AF. This is especially important for elderly patients as renal function is known 
to decline more rapidly in patients with AF (Hijazi et al., 2016). 
While previous studies have demonstrated, through simulations, that there would be 
clinically important risks to prescribing practice for dabigatran etexilate if alternatives to 
the Cockcroft-Gault equation were used to estimate renal function (Dowling et al., 2013; 
Hellden et al., 2013; Hudson et al., 2014; MacCallum et al., 2013), none have 
investigated this with patient outcomes data. This study is the first, to our knowledge, to 
examine a large cohort of patients dispensed dabigatran etexilate and investigate the 
impact of different estimates of renal function on adverse outcomes. 
Of the methods investigated only high doses of dabigatran etexilate estimated by the 
Cockcroft-Gault equation showed a statistically significant increased hazard ratio of 2.32 
(95% CI: 1.22 4.42; p=0.001) for a haemorrhage. The present study indicates that the 
Cockcroft-Gault equation is a better predictor of appropriate dabigatran etexilate dosing 
than the CKD-EPI and CKD-EPI-BSA equations as they do not effectively prevent the 
recommendation of inappropriately high doses of dabigatran. This can be attributed to 
those patients whose renal function is nearing the recommended dose stratification limits 
and being over estimated by the CKD-EPI and CKD-EPI-BSA equations. Thus, not 
receiving a clinically appropriate dose reduction based on renal function and suffering a 
haemorrhage. Additionally, the equations CKD-EPI and CKD-EPI-BSA showed only 
fair to moderate agreement (weighted Kappa coefficients of 0.47 and 0.71 respectively) 
with the Cockcroft-Gault equation for this cohort of patients. This indicates that the 
Cockcroft-Gault equation should not be substituted by the CKD-EPI and CKD-EPI-BSA 
equations for estimating renal function when determining the dose of dabigatran 
etexilate, especially in the elderly. 
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These findings are important, especially for elderly patients, as rates of bleeding and 
CVA increase as renal function deteriorates (Hijazi et al., 2013; Hijazi et al., 2016) and 
declines in renal function are known to occur with aging (Lindeman et al., 1985). 
Additionally, a previous study has reported that elderly patients, receiving dabigatran 
etexilate, were at a greater risk of major gastrointestinal haemorrhagic bleeding compared 
with warfarin (Graham et al., 2015). This makes it imperative that a clinically appropriate 
dose of dabigatran etexilate is selected and hence the Cockcroft-Gault estimator of renal 
function is used. 
The limitations of this study include the NMDS only capturing patient data for those who 
require in-patient hospitalisation for a duration of more than 4 hours. Therefore, any 
outcomes of interest that did not meet these criteria, for example a haemorrhage or CVA 
that resulted in death without an in-patient hospitalisation, would not be included in the 
dataset resulting in possible under estimations. Additionally, there is the possibility of 
errors in the clinical information from the NMDS and primary care dataset. These errors 
could result in inclusion or exclusion of clinical outcomes of interest. Although, it has 
been reported that there is high sensitivity when using ICD-9-CM to identify 
haemorrhagic events with 93% sensitivity and 88% specificity to identifying a definite 
major haemorrhagic event (Arnason et al.). Similarly, it has been reported that using 
ICD-10 to identify CVA has a positive predictive value (PPV) of close to or greater than 
90% and therefore adequate to identify CVA (Woodfield et al., 2015). We assumed that 
the ICD-10-AM used to identify haemorrhagic events had high sensitivity and specificity 
and those used to identify CVA had a high PPV. These limitations contribute to 
background variability but would not be expected to contribute to a systematic bias. 
There was not access to reliable information about patient comorbidities and as their 
Chapter three Renal function estimator influences outcomes with dabigatran
114 
interaction with dabigatran etexilate treatment is not accounted for in this study there is 
possible bias in outcome profiles. For example, it was not possible to determine the 
individual patient CHA2DS2-VASc and HAS-BLED scores. These assessments quantify 
thromboembolic risk versus bleeding risk and can result in dose recommendations that 
differ from those derived solely from renal function. With no diagnostic information 
contained in the NMDS it was therefore not possible to investigate disease specific dose 
regimens by indication. These limitations would all be expected to contribute to random 
variability but would not be expected to result in any systematic bias. Additionally, the 
PC only provides information relating to the dispensing of medications and it is not 
possible to confirm if the patients within this cohort have adhered to the prescribed 
regimen. The MDRD-4 equation was not analysed in this study as this test is now 
infrequently used in New Zealand with CKD-EPI the estimate of choice for laboratory 
reporting. Therefore, the MDRD-4 equation was unlikely to have been utilised by 
clinicians to determine dosing and thus its relative performance has not been investigated. 
Also, receiver operating characteristic plot analysis did not indicate that the different 
renal function estimations were reliable predictors of outcomes. This might be due to 
dose modifications that may have been made based on the test result or patient covariates 
which would obscure the relationship. The main strength of this study is the inclusion of 
a large cohort of patients with a similar age profile to that of the original clinical trial, 
with sufficient sample size to provide adequate information about the effects of different 
renal function estimators on dabigatran etexilate outcomes for an entire population. 
The results of the present study indicate that when determining dabigatran etexilate dose 
adjustments for renal function, clinicians should use the method utilised in the clinical 
trial pharmacokinetic studies (i.e. the Cockcroft-Gault equation). This is particularly 
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pertinent in primary care as dabigatran prescribing is increasingly used in this 
setting (MacCallum et al., 2013; Simpson et al., 2017). Although there is familiarity with 
estimating renal function using the Cockcroft-Gault equation in hospital practice, this is 
not the case in primary care (MacCallum et al., 2013). Additionally, it has been 
previously reported that clinicians predominately use eGFR reported by 
laboratories (Howey et al., 2013) therefore alternate methods of reporting renal function 
estimated, via the Cockcroft-Gault equation, needs to be investigated. This could be in 
 Furthermore, 
with it being reported that CKD-EPI gives the best estimation of glomerular filtration 
rate (Michels et al., 2010) it may be prudent that regulatory bodies, such as the FDA and 
EMA, consider mandatory use of this method for the evaluation of medicines in patients 
with decreased renal function. 
3.2.6 Conclusions 
Both CKD-EPI and CKD-EPI-BSA equations significantly overestimated renal function 
in the elderly population compared with the Cockcroft-Gault equation. This may lead to 
dose selection errors for dabigatran etexilate, particularly for those with severe 
impairment, increasing the risk of an adverse outcome. Hence, CKD-EPI and CKD-EPI-
BSA equations should not be substituted in place of the Cockcroft-Gault equation in older 
adults for the purpose of renal dosage adjustments. 
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Supplementary Table 1 ICD-10-AM codes used for the identification of haemorrhage, 
thromboembolism/CVA and Unspecified CVA. 
Adverse event type ICD-10-AM Code 
Haemorrhage D683 (Hemorrhagic disorder due to 
extrinsic circulating anticoagulants), 
H431 (Vitreous hemorrhage), I601 
(Nontraumatic subarachnoid hemorrhage 
from middle cerebral artery), I609 
(Nontraumatic subarachnoid 
hemorrhage, unspecified), I610 
(Nontraumatic intracerebral hemorrhage 
in hemisphere, subcortical), I611 
(Nontraumatic intracerebral hemorrhage 
in hemisphere, cortical), I613 
(Nontraumatic intracerebral hemorrhage 
in brain stem), I615 (Nontraumatic 
intracerebral hemorrhage, 
intraventricular), I616 (Nontraumatic 
intracerebral hemorrhage, multiple 
localized), I618 (Other nontraumatic 
intracerebral hemorrhage), I619 
(Nontraumatic intracerebral hemorrhage, 
unspecified), I620 (Nontraumatic 
subdural hemorrhage), I629 
(Nontraumatic intracranial hemorrhage, 
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unspecified), I671 (Cerebral aneurysm, 
nonruptured), K250 (Acute gastric ulcer 
with hemorrhage), K254 (Chronic or 
unspecified gastric ulcer with 
haemorrhage), K260 (Acute duodenal 
ulcer with hemorrhage), K264 (Chronic 
or unspecified duodenal ulcer with 
hemorrhage), K266 (Chronic or 
unspecified duodenal ulcer with both 
hemorrhage and perforation), K274 
(Chronic or unspecified peptic ulcer, site 
unspecified, with hemorrhage), K284 
(Chronic or unspecified gastrojejunal 
ulcer with hemorrhage), K290 (Acute 
gastritis with bleeding), K625 
(Hemorrhage of anus and rectum), K661 
(Hemoperitoneum), K920 
(Hematemesis), K921 (Melena), K922 
(Gastrointestinal hemorrhage, 
unspecified), N028 (Recurrent and 
persistent hematuria with other 
morphologic changes), N029 (Recurrent 
and persistent hematuria with unspecified 
morphologic changes), N938 (Other 
specified abnormal uterine and vaginal 
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bleeding), N939 (Abnormal uterine and 
vaginal bleeding, unspecified), N950 
(Postmenopausal bleeding), R042 
(Hemoptysis), R048 (Hemorrhage from 
other sites in respiratory passages), R58 
(Hemorrhage, not elsewhere classified)
Thromboembolism/CVA I634 (Cerebral infarction due to 
embolism of other cerebral artery), I631 
(Cerebral infarction due to embolism of 
precerebral arteries), I633 (Cerebral 
infarction due to thrombosis of cerebral 
arteries), I630 (Cerebral infarction due to 
thrombosis of precerebral arteries), I632 
(Cerebral infarction due to unspecified 
occlusion or stenosis of precerebral 
arteries), I639 (Cerebral infarction, 
unspecified), I744 (Embolism and 
thrombosis of arteries of extremities, 
unspecified), I743 (Embolism and 
thrombosis of arteries of the lower 
extremities), I742 (Embolism and 
thrombosis of arteries of the upper 
extremities), I652 (Occlusion and 
stenosis of carotid artery), I663 
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(Occlusion and stenosis of cerebellar 
arteries), I660 (Occlusion and stenosis of 
middle cerebral artery), I653 (Occlusion 
and stenosis of precerebral arteries, not 
resulting in cerebral infarction), I668 
(Occlusion and stenosis of other cerebral 
arteries), I658 (Occlusion and stenosis of 
other precerebral arteries), I669 
(Occlusion and stenosis of unspecified 
cerebral artery), I659 (Occlusion and 
stenosis of unspecified precerebral 
artery), G458 (Other transient cerebral 
ischemic attacks and related syndromes), 
I64 (Other transient cerebral ischemic 
attacks and related syndromes), G459 
(Transient cerebral ischemic attack, 
unspecified), G450 (Vertebro-basilar 
artery syndrome)
Unspecified CVA I635 (Cerebral infarction due to 
unspecified occlusion or stenosis of 
cerebral arteries), I679 (Cerebrovascular 
disease, unspecified), I678 (Other 
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4 Paper THREE Exposure response supports therapeutic 




response supports therapeutic drug monitoring for dabigatran etexilate in patients with 
atrial fibrillation . This manuscript was published in TH Open in 2019. TH Open 2019, 
03 (03), e210-e215, doi: 10.1055/s-0039-1693486 (B. H. Simpson, Reith, Medlicott, & 
Smith, 2019). See Appendix 5. 
Dabigatran etexilate has been promoted as not requiring routine coagulation monitoring, 
unlike its predecessor warfarin. This apparent lack of required testing and possible effects 
on patient outcomes has been controversial in recent years. Currently it is possible to 
measure plasma concentrations of dabigatran, but the thresholds have yet to be validated. 
O o dabigatran will help enable clinicians to ensure that 
decisions are based on the plasma concentrations that represent a balance between 
avoiding bleeding and preventing thrombosis. 
Therefore, the aim of this chapter/study was to investigate the relationship between 
dabigatran etexilate exposure and adverse response in real-world patients. 
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Background: Dabigatran etexilate has become widely used for the prevention of stroke 
in patients with non-valvular atrial fibrillation (NVAF). Currently, there is limited 
information in real-world patients relating to dabigatran etexilate exposure and response. 
Methods: This retrospective cohort study used administrative health data for NVAF 
patients dispensed dabigatran etexilate between 1 July 2011 and 31 December 2015. 
Outcomes of cerebrovascular accident (CVA), systemic embolism and haemorrhage 
were extracted. Simulated pharmacokinetic parameters were obtained using a published 
population pharmacokinetic model of dabigatran etexilate. Area under the curve 
calculated for a 24-hour period at steady state (AUCss), the exposure parameter, was 
derived using these simulations and the dosing data and the exposure-response 
relationship was investigated. The risk of adverse outcomes at AUCss quartiles was 
compared using Poisson regression and expressed using incidence rate ratios (IRR) (95% 
CI) adjusted for known potential confounders. 
Results: In total, 2660 NVAF patients had been dispensed dabigatran etexilate. For these 
patients there was a decreased risk of haemorrhage (0.51, 0.32 0.79) when dabigatran 
AUCss was in the second quartile range of 1.70 1.96 mg*h/L and 
thromboembolism/CVA (0.34, 0.16 0.76) when was in the third quartile range of 1.97
2.26 mg*h/L. An increased risk of haemorrhage (1.68, 1.18 2.38) was observed when 
AUCss was in the fourth quartile range of 2.27 12.76 mg*h/L. 
Conclusion: An exposure response relationship for dabigatran etexilate was described, 
where the most effective response was observed when AUCss was in the range of 1.70 
to 2.26 mg*h/L. Hence, it is feasible to develop guidance for optimal dosing to improve 
outcomes for patients with NVAF. 




The direct oral anticoagulant (DOAC), dabigatran etexilate, has become widely used 
since its approval for the prevention of stroke in patients with non-valvular atrial 
fibrillation (NVAF) (Simpson et al., 2017) but has been associated with a number of 
adverse outcomes (Bell et al., 2012; Thorne et al., 2014). Despite this there is paucity of 
information for the dose response for this important medication. 
Dabigatran etexilate is normally administered as a twice daily fixed dose regimen with 
the dosage modified by age and/or creatinine clearance, use of concomitant drugs and 
thromboembolic risk versus bleeding risk (Boehringer Ingelheim (N.Z.) Limited, 2017). 
As with other DOAC medications, dabigatran etexilate exhibits a more predictable 
pharmacokinetic and pharmacodynamics profile when compared with vitamin K 
antagonists (Dale Brian et al., 2015). 
Although dabigatran etexilate has been promoted as not requiring routine coagulation 
monitoring this has become controversial (Cohen, 2014). Certainly, there are specific 
clinical situations where assessment of the anticoagulation effect may be required, such 
as: for those who are bleeding, before and after administration of the dabigatran-specific 
antidote idarucizumab (Praxbind®), evaluation of therapy failure in case of thrombosis, 
renal failure, before emergency surgery, before potential thrombolysis in ischaemic 
stroke, at extremes of body weight, concomitant use of drugs known to affect 
pharmacokinetics of dabigatran etexilate and in cases of suspected non-
adherence (Comuth et al., 2018). Moreover, it has been reported that if TDM was 
undertaken major bleeds could be reduced by 30-40% when compared to well controlled 
warfarin (Cohen, 2014). 
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Currently, the sponsor indicates that an increased risk of bleeding can possibly be 
detected by via elevated coagulation tests such as thrombin time (TT), ecarin clotting 
time (ECT) and activated thromboplastin time (aPPT) (Boehringer Ingelheim 
International GmbH). However, there are limitations to the aPTT; such as the test having 
limited sensitivity making it unsuitable for precise quantification of the anticoagulant 
effect and the ECT test not being readily available or useful in the absence of 
standardisation means that there is limited utility of these tests in clinical 
practice (Douxfils et al., 2017). TT is a very useful test for detecting low levels of 
dabigatran etexilate in plasma (Chin, Wright, Patterson, et al., 2014). However, thrombin 
time becomes rapidly unclottable in the presence of low dabigatran etexilate 
concentrations, and therefore cannot be used for the overall expected drug concentration 
measurement (Amiral et al., 2016). In relation to treatment failure, it has been reported 
that the sponsor believes that due to the low number of endpoint events for venous 
thromboembolism (VTE) patients and the availability of only pharmacokinetic data from 
clinical trials, only a limited exposure-response analysis could be undertaken for VTE 
prevention (Committee for Medicinal Products for Human Use (CHMP), 2014). 
Therefore, there has been no guidance provided for monitoring patients for possible 
subtherapeutic treatment (Committee for Medicinal Products for Human Use (CHMP), 
2014). 
Despite it now being feasible to determine dabigatran plasma concentrations (Poli et al., 
2017; Rottenstreich et al., 2018), the thresholds are yet to be validated to ensure that 
clinical decisions based on the plasma concentrations represent the balance between 
avoiding bleeding and preventing thrombosis (Douxfils et al., 2017). While it has been 
shown that there is an association between plasma concentrations and bleeding risk the 
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clear cut-offs for bleeding and thromboembolism/cerebrovascular accident (CVA) risk 
are not yet established (Douxfils et al., 2017). With no reported reference ranges for 
dabigatran etexilate therapeutic drug monitoring (TDM), further studies would help 
clarify this issue. 
The aim of the present study was to investigate the relationship between dabigatran 
etexilate exposure and adverse response in real-world patients. 
4.2.3 Methods 
4.2.3.1 Identification of study cohort 
This was a retrospective cohort study using administrative health data from New Zealand. 
The databases accessed were the Best Practice Intelligence (BPI) database operated by 
Best Practice Advocacy Centre Clinical Solutions, New Zealand (Best Practice Inc) and 
the New Zealand Ministry of Health Pharmaceutical Collection (New Zealand Ministry 
of Health, 2016b) (PC). The BPI database is a secure, internet based, reporting tool that 
uses data downloaded from the enrolled general practice patient electronic health record 
(EHR) and covers approximately 20% of the New Zealand population. The PC contains 
prescription details about pharmaceutical dispensing claims for dabigatran etexilate 
along with other prescribed medicines as well as information on gender, date of birth, 
age, ethnicity, deprivation index score, frequency and quantity dispensed for all of the 
New Zealand population. The study population included patients; with a diagnosis of 
NVAF, aged 18 years or older, had at least one dispensing of dabigatran etexilate during 
the study period between 1 July 2011 (when dabigatran etexilate became available in 
New Zealand) and 31 December 2015, serum creatinine measurements within 60 days 
before or 30 days after their first dispensing of dabigatran etexilate, and bodyweight 
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measurements within 1 year before or after their first dispensing of dabigatran etexilate. 
If a patient had a diagnosis of venous thromboembolism or deep-vein thrombosis 
concurrently recorded with NVAF during the study period, they were excluded. The 
information from differe onal 
Health Index number (NHI; a life-long unique identifier for all interactions with the New 
Zealand health system) to ensure patient anonymity. Ethical approval was obtained from 
the University of Otago, New Zealand Ethics Committee (Reference: HD15/054) (See 
Appendix 1 & 2). 
4.2.3.2 Patient covariates 
Dispensed medications, patient demographic and covariate data were extracted from the 
PC and BPI databases who meet the inclusion criteria. Data relating to medications that 
are reported to have an impact on area under the curve (AUC) (verapamil, amiodarone 
and proton pump inhibitors) (Liesenfeld et al., 2011) when taken concomitantly with 
dabigatran etexilate were extracted from the PC database for patients who had both 
medications dispensed within 90 days. As it has also been reported that patients with 
heart failure have an increase in AUC (Liesenfeld et al., 2011), data relating whether a 
patient has a diagnosis of heart failure while being treated with dabigatran etexilate were 
extracted from the BPI database. Patients were stratified into age groupings of under 65 
years, 65-74 years, 75-79 years and over 80 years to align to both regulatory and the 
categories used by the sponsor to guide dosing (Boehringer Ingelheim (N.Z.) Limited, 
2017; Committee for Human Medicinal Products (CHMP), 2007; U.S. Department of 
Health and Human Services Food and Drug Administration, 2012). 
Estimation of renal function If multiple serum creatinine or bodyweight measurements 
were recorded, the measurement closest to the initiation of dabigatran etexilate initiation 
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was used. Weight measurements more than five standard deviations from the mean were 
considered to be due to data entry errors and were excluded. 





CrCl = creatinine clearance, 
age = age in years, 
weight = weight in kg, 
SCr = serum creatinine (expressed in mg/dL). 
 
Equation 1: Cockcroft-Gault 
Derived area under the curve at steady state (AUCss)  Simulated pharmacokinetic 
parameters; volume of distribution, bioavailability and clearance were obtained using a 
previously published population pharmacokinetic two compartment model of dabigatran 
etexilate (Liesenfeld et al., 2011). Simulated individual pharmacokinetic parameters for 
the first compartment [clearance (CL), central volume of distribution (V1) and 
bioavailability (F)] were determined for patients included in the study cohort using the 
previously published nonlinear mixed-effects model using Phoenix NLME Version 7. 
AUCss for a 24-hour period, the exposure parameter, was derived using these simulated 
estimates and the dosing data obtained from the PC. The second compartment parameters 
were fixed [intercompartmental clearance (Q = 35.5 L/h) and volume distribution of 
peripheral compartment (Vper = 345 L)] 
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4.2.3.3 Patient Outcomes 
The outcomes of interest were: (1) any admission to hospital for haemorrhage or, (2) 
thromboembolism/CVA. These were extracted from the New Zealand Ministry of Health 
National Minimum Dataset (NMDS) (2015). The NMDS is the national record of all 
public and private hospital discharge information, including coded clinical data for 
admissions greater than four hours for all of the New Zealand population. This database 
uses the International Classification of Diseases and Related Health Problems Tenth 
Revision, Australian Modification (ICD-10-AM) to record the diagnosis (National 
Centre for  Classification in Health, 2008). The date of admission to hospital was also 
extracted and aligned with the preceding dispensing of dabigatran etexilate for that 
patient. Patients were followed from their first dispensing of dabigatran etexilate until 
the date of hospitalisation, cessation of dabigatran etexilate treatment or study end. 
4.2.3.4 Statistical analyses 
Continuous variables were tested for normal distribution by the skewness and kurtosis 
test. Normally distributed data are presented as the mean ± standard deviation and non-
normally distributed data as the median (interquartile range). Categorical variables were 
expressed as percentages.  
To evaluate the exposure-response relationship, patients were stratified into AUCss 
exposure quartiles (Q1-Q4). As there were differences in individual patient follow up 
time, the risk of haemorrhage or thromboembolism/CVA between AUCss quartiles was 
compared using Poisson regression (Coleman, 1964). The resulting estimates were 
expressed using incidence rate ratios (IRR) (95% confidence intervals (CI)) (Coleman, 
1964). As exposure changed over time the standard hazard functions could not be fitted 
and rates were calculated per unit time exposure from which rate ratios (which are 
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unitless) were calculated. Models were adjusted for known potential pharmacodynamic 
confounders: gender, age 75-79 years, age 80 years and over, M ori and Pacific Peoples 
ethnicities and deprivation rating (continuous) (Simpson et al., 2018b). Results were 
considered statistically significant if p < 0.05. 
Statistical analyses were performed using Stata/IC (Version 14.2, StataCorpLP, TX, 
USA). 
4.2.4 Results 
4.2.4.1 Patient characteristics 
There were 2660 individual patients identified in the databases who had been dispensed 
dabigatran etexilate with a diagnosis of AF, aged 18 years or more, and who had one or 
more serum creatinine and bodyweight measurement recorded. The median age of 
patients in this cohort was 73 years (IQR: 66-79.5 years) and 1525 (57.3%) were male. 
The median bodyweight was 85 kg (IQR: 72-100 kg). The median creatine clearance was 
74.1 ml/min (IQR: 56.1-98.2). Overall patient covariate information is displayed in 
Table 15.
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Table 15 Individual patient covariate information 






Male 1525 57.3 3023 
Female 1135 42.7 2156 
Age    
<65 years 554 20.8 952 
65 74 years 922 34.7 1836 
75 79 years 519 19.5 1043 




European 2098 78.9 4075 
 315 11.8 587 
Pacific Peoples 65 2.4 129 
Asian 24 0.9 63 
MELAA 3 0.1 7 
Other Ethnicity 155 5.8 287 




Severe impairment (CrCl < 30 mL/min) 43 1.6 58 
 < 50 mL/min) 425 16.0 732 
 < 80 mL/min) 1036 39.0 2081 
 < 120 mL/min) 818 30.8 1631 
No impairment (CrCl > 120 mL/min) 338 12.7 647 






Verapamil 42 1.6 85 
Amiodarone 165 6.2 257 
Proton Pump Inhibitor 1186 44.6 2268 
New Zealand deprivation score    
1 Least deprived 154 5.8 299 
2 165 6.2 311 
3 224 8.4 471 
4 206 7.7 372 
5 183 6.9 346 
6 212 8.0 397 
7 224 8.4 430 
8 192 7.2 372 
9 232 8.7 458 
10 Most deprived 200 7.5 378 
Not recorded 668 25.1 1315 
Formulation Dispensed (at baseline)    
75 mg 43 1.6 2 
110 mg 1375 51.7 127 
150 mg 1242 46.7 95 
Formulation Dispensed (for all dispensings)    
75 mg 1189 1.8 80 
110 mg 34670 53.1 2631 
150 mg 29374 45.0 2438 
Abbreviation: MELAA, Middle Eastern, Latin American or African ethnicity. 
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4.2.4.2 Patient outcomes 
Approximately 4% of patients required hospitalisation due to an adverse event occurring 
while being treated with dabigatran etexilate; there were 87 (3.3%) haemorrhagic events 
with a median age of 74 years (IQR: 70-81 years) and 29 (1.1%) thromboembolic/CVA 
events with a median age of 72 years (IQR: 68-79 years). 
4.2.4.3 Exposure derived area under the curve 
There were 65233 individual prescriptions for dabigatran etexilate with a total 5149 
person years supplied. The median AUCss was 2.0 mg*h/L (IQR: 1.7-2.3 mg*h/L) and 
when stratified by quartile each had the following results; 
 Q1 had a mean of 1.48 mg*h/L (range: 0.79 1.69 mg*h/L),  
 Q2 had a mean of 1.83 mg*h/L (range: 1.70 1.96 mg*h/L),  
 Q3 had a mean of 2.11 mg*h/L (range: 1.97 2.26 mg*h/L),  
 Q4 had a mean of 2.74 mg*h/L (range: 2.27 12.76 mg*h/L).  
Simulated pharmacokinetic parameters are summarised in Table 16. Those with an 
AUCss in the second and third quartiles had a reduced risk of haemorrhage [IRR: 0.51, 
95%CI, 0.32-0.79; p = 0.003] and thromboembolism/CVA [IRR: 0.34, 95%CI, 0.16-
0.76; p = 0.008] respectively while those with an AUCss in the fourth quartile had an 
increased risk of a haemorrhage [IRR: 1.68, 95%CI, 1.18 2.38; p = 0.004] ( 
Table 17) 
.
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Table 16 Summary of simulated pharmacokinetic parameters (n = 65,233) 
Simulated 
parameter 
mean (SD) median IQR 
CL (ml/min) 69.3 (17.6) 68.8 56.9-81.2 
V1 (L) 710.1 (117.6) 697.4 630.0-775.1 
F 1.0 (0.1) 1.0 0.9-1.0 
Abbreviations: CL, clearance; F, bioavailability; IQR, 
interquartile range; SD, standard deviation; V1, central volume 
of distribution. 
Note: Fixed parameters; Q (35.5L/h) and Vper (345 L). 
 
Table 17 Poisson regression expressed as adjusted incidence rate ratios (IIR) and 95% 
confidence interval (95%CI) of haemorrhage, thromboembolism/CVA by AUCss 
quartiles (n = 65,233) 
 Haemorrhage Thromboembolism/CVA 
AUCss IRR (95%CI) z p>|z| IRR (95%CI) z p>|z| 
Quartile 1 0.9 (0.61 1.33) -0.52 0.606 1.31 (0.73 2.34) 0.89 0.371 
Quartile 2 0.51* (0.32 0.79) -3.01 0.003 1.49 (0.87 2.55) 1.45 0.146 
Quartile 3 1.13 (0.81 1.59) 0.71 0.478 0.34* (0.16 0.76) -2.66 0.008 
Quartile 4 1.68*(1.18 2.38) 2.89 0.004 1.20 (0.68 2.12) 0.62 0.536 
Abbreviations: AUCss, area under the curve at steady state; CVA, cerebrovascular 
accident; IRR, adjusted incidence rate ratio for potential confounders: gender, age 75 
Peoples ethnicities and deprivation rating 
(continuous). 
* Statistically significant 
4.2.5 Discussion 
This study demonstrates the feasibility of using measures of dabigatran etexilate 
pharmacokinetic exposure to optimise dosing and potentially improve patient outcomes. 
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The present study utilises a novel approach of combining individual patient data, 
treatment outcomes and a previously developed population pharmacokinetic model of 
dabigatran etexilate. AUCss for each individual patient was derived and adjusted IRR, at 
each AUCss quartile calculated. We observed that there was a statistically significant 
greater risk for a haemorrhage observed for those patients with an AUCss in the fourth 
quartile, while there was a statistically significant protective effect observed in the second 
quartile. In relation to thromboembolism, there was also a protective effect observed for 
those patients with an AUCss in the third quartile. Therefore, adjusting doses to achieve 
an AUCss that is in the range of 1.70 to 2.26 mg*h/L may result in better outcomes for 
patients. 
Additionally, the median age of our cohort was 73 years which is older than that of 
patients enrolled in the dabigatran etexilate clinical trial (Connolly et al., 2009). It is 
acknowledged in the literature that elderly patients are at an overall increased risk of 
adverse outcomes with other studies having demonstrated that increasing age was a risk 
factor for having increased levels of dabigatran etexilate (Reilly et al., 2014; 
Rottenstreich et al., 2018). Therefore, the present study is able to provide a basis for 
developing reference ranges for optimal dosing for this at-risk and under-studied 
population. 
Currently it is not clear if TDM would be cost effective in the clinical setting. It has been 
recently reported that with the rapidly growing use of DOACs there is increasing debate 
about the utility of point-of-care testing (Rottenstreich et al., 2018). Despite these tests 
being available they are more expensive than traditional coagulation tests which may 
limit their utilisation. With traditional coagulation tests having limited use in clinical 
practice, due to either poor sensitivity or standardisation (Douxfils et al., 2017), it has 
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been suggested that point-of-care use in selected clinical situations may counter-balance 
their cost (Rottenstreich et al., 2018). Additionally, to achieve the target AUCss, the 
dosing schedule may need altering (for example: extending or reducing dose intervals or 
combining different available formulation strengths) and dose simulations might clarify 
this point. Therefore, the present study can aid in the future economic evaluation for cost 
effectiveness of TDM utility for dabigatran etexilate by providing treatment reference 
ranges conducive to favourable patient outcomes. 
This study provides a preliminary clinical therapeutic reference range for dabigatran 
etexilate to help guide further studies investigating optimal dosing. Additionally, we are 
able to provide a real-world study population that has sufficient numbers to examine 
subtherapeutic treatment, a gap in knowledge identified in the literature (Committee for 
Medicinal Products for Human Use (CHMP), 2014). With dabigatran etexilate TDM 
suggested to possibly reduce major bleeds by 30-40%, compared to well controlled 
warfarin (Cohen, 2014), this study expands on this by providing a reference range that 
could be translated into the clinical setting along with a possible decrease in thrombotic 
events. 
The limitations of this study include the NMDS only capturing patient data for those who 
require in-patient hospitalisation for a duration of more than 4 hours. Therefore, any 
outcomes of interest that did not meet these criteria, for example a haemorrhage or 
thromboembolism/CVA that resulted in death without an in-patient hospitalisation, 
would not be included in the dataset resulting in possible under estimations. Additionally, 
there is the possibility of errors in the clinical information from the NMDS and primary 
care dataset. These errors could result in inclusion or exclusion of clinical outcomes of 
interest. Although, it has been reported that there is high sensitivity when using ICD-9-
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CM to identify haemorrhagic events with 93% sensitivity and 88% specificity to 
identifying a definite major haemorrhagic event (Arnason et al.). Similarly, it has been 
reported that using ICD-10 to identify thromboembolism/CVA has a positive predictive 
value (PPV) of close to or greater than 90% and therefore adequate to identify 
thromboembolism/CVA (Woodfield et al., 2015). We assumed that the ICD-10-AM used 
to identify haemorrhagic events had high sensitivity and specificity and those used to 
identify thromboembolism/CVA had a high PPV. These limitations contribute to 
background variability but would not be expected to contribute to a systematic bias. 
Additionally, the PC only provides information relating to the dispensing of medications 
and it is not possible to confirm if the patients within this cohort have adhered to the 
prescribed regimen. Also, the population pharmacokinetic model utilised did not 
included covariate effects for other drug interactions (such as atorvastatin, rifampicin, 
clarithromycin) as there were no published validated models. Although risk factors were 
included in the exposure model utilised, HAS-BLED and CHA2DS2-VASc covariates 
were not. However, known risk factors in our population were included (such as 
ethnicity, increasing age and deprivation score). The main strength of this study is the 
inclusion of a large cohort of patients with sufficient sample size to provide adequate 
information about dabigatran etexilate exposure response. 
4.2.6 Conclusion 
This retrospective cohort demonstrated that there is a relationship between dabigatran 
etexilate exposure and adverse response in real-world patients. It has established that it 
is feasible to provide guidance for optimal dosing to improve outcomes for patients with 
AF. This is particularly relevant for elderly patients who are at greater risk of adverse 
treatment outcomes.  
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5 Paper FOUR  Monitoring the use of dabigatran etexilate 
for stroke prevention: compliance with renal function 
guidelines. 
5.1 Preface 
The following chapter contains a submitted original manuscript titled, Monitoring the 
use of dabigatran etexilate for stroke prevention: compliance with renal function 
. This manuscript was submitted to the Journal of Primary Health care in 
December 2019. 
As described in chapter one, dabigatran etexilate is predominantly (80%) renally excreted 
drug. Due to this, it is important that appropriately timed renal function testing is 
undertaken to reduce the risk of bleeding due to unwanted drug accumulation. Previous 
audits into dabigatran etexilate use and adherence to renal function testing in New 
Zealand primary care have shown high adherence in the first year of treatment. 
Unfortunately, these audits did not investigate the proximity of the testing to times 
recommended by current clinical guidelines. 
Therefore, the aim of this chapter/study was to investigate if clinically appropriate renal 
function testing recommendations were being undertaken in New Zealand primary care 
for NVAF patients prescribed dabigatran etexilate. 
  




5.2 Monitoring the use of dabigatran etexilate for stroke 
prevention: compliance with renal function guidelines 
Bryan Henry Simpson1, David M Reith2, Natalie J Medlicott1, Alesha J Smith1  
1University of Otago New Zealand's National School of Pharmacy Dunedin, NZ 
2University of Otago Department of Women's and Children's Health Dunedin, NZ 
 
Journal of Primary Health Care: Submitted December 2019 (B. H. Simpson et al., 
2019) 
 
Statement of contribution 
BHS, DMR, NJM and AJS conceived this study. BHS further refined and finalised the 
research protocol. BHS conducted the research including data aggregation from the 
various databases. BHS conducted all analysis and produced the first draft of the research 
manuscript. All authors subsequently contributed to the review and revision of the 
manuscript and read and approved the final manuscript. 
  
Chapter five Compliance with renal function guidelines
146 
Abstract
Introduction: Dabigatran etexilate has become widely used in New Zealand, but 
information relating to when renal function monitoring is being undertaken is lacking.  
Aim: To investigate if clinically appropriate renal function monitoring is being 
undertaken in New Zealand primary care for stroke prevention in non-valvular atrial 
fibrillation (NVAF) patients prescribed dabigatran etexilate. 
Methods: 
extracted from national administrative databases for the period 01 July 2011 to 31 
December 2015. The proportion of patients who had serum creatinine measurements at 
close proximity to treatment initiation and 12 months post were assessed with the 95% 
confidence interval and compa test. Log-rank tests for univariate 
analysis (gender, age, ethnicity and deprivation) effects on serum creatinine testing at 
dabigatran etexilate treatment initiation and 12 months post were performed. 
Results: There were 1,948 patients identified that had been dispensed dabigatran 
etexilate with available primary care health data. A total of 1,752 (89.9% [95%CI; 88.5-
91.2]) patients had a renal function test at dabigatran etexilate initiation. There were 929 
(72.8% [95%CI; 70.2-75.2]) patients who received one or more years supply of 
dabigatran and of these 207 (22.3% [95%CI; 19.6.6-25.1]) had a serum creatinine test 
one year after initiation. Demographic univariate analysis yielded insignificant log-rank 
tests for association with having serum creatinine measurements except for Pacific 
Peoples. 
Discussion: There appears to be sub-optimal adherence to renal function monitoring for 
NVAF patients who receive more than 12 months treatment with dabigatran in the New 
Zealand primary care setting.  





The direct thrombin inhibitor, dabigatran etexilate, has become widely used in New 
Zealand with 51% of patients receiving oral anticoagulation now being treated with this 
medication (Simpson et al., 2018b). Approximately 80% of dabigatran etexilate is 
excreted renally (Ezekowitz et al., 2009), therefore it is important to ensure that 
appropriately timed renal function testing is undertaken to reduce the risk of bleeding 
due to drug accumulation (Douxfils et al., 2017; Hankey et al., 2011; Simpson et al., 
2019). 
When dabigatran etexilate gained full subsidy in New Zealand in 2011, the national 
pharmaceutical management organisation (PHARMAC) commissioned the predominate 
primary care electronic health record (EHR) system provider to generate a computerised 
prescribing assistant. This prescribing assistant, among other functions, prompted the 
. The 
prescribing assistant only activated for the first dabigatran etexilate prescription and not 
for any that followed (Figure 12).  
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Figure 12 Example image from electronic health record of Prescribing Assistant for first 
dabigatran etexilate prescriptions. 
The present study investigates renal function monitoring in patients with non-valvular 
atrial fibrillation (NVAF) who have had dabigatran etexilate initiated by primary care 
physicians. Patients with NVAF often can have multiple co-morbidities, including 
reduced renal function (Lane et al., 2013; Simpson et al., 2018a) and thus is an important 
consideration when dabigatran etexilate dosing decisions are being made (Drouet et al., 
2016). This is due to plasma concentrations of dabigatran etexilate being highly 
correlated with renal function (Gong et al., 2013), and it is expected that levels outside 
the optimum range are potentially associated with higher risk of adverse 
outcomes (Simpson et al., 2019). Renal function is easily accessed during routine clinical 
care via estimation of creatinine clearance following a serum creatinine test (Cockcroft 
et al., 1976). Currently, in New Zealand, data relating to adherence to appropriately timed 
renal function testing for dabigatran etexilate are lacking. 




Previous published audits of New Zealand dabigatran etexilate patients have shown 
100% adherence to renal function testing protocols at treatment initiation and between 
63-90% adherence in the first year for those being treated for more than one 
year (McBain et al., 2018; Thorne et al., 2015). In relation to the testing in the first year, 
the audits investigated if a patient receiving dabigatran etexilate had a renal function test 
undertaken anytime in the 12 months following treatment initiation (Best Practice 
Advocacy Centre (bpacnz)). Current clinical guidance recommends that patients undergo 
tests every 12 months or more often if clinically indicated (Best Practice Advocacy 
Centre (bpacnz), 2011; Boehringer Ingelheim (N.Z.) Limited, 2017; Medsafe 
Pharmacovigilance Team, 2015). Therefore, as these audits do not account for the 
proximity of the test to the 12 month anniversary of treatment initiation it is not possible 
to determine if testing is being undertaken at these clinically appropriate times. Thus, 
there may be misrepresentation of the number of patients undergoing renal function 
testing at clinically appropriate times. Furthermore, there is a lack of published data in 
the literature that describes when clinicians are undertaking renal function testing for 
those patients prescribed dabigatran etexilate. 
The aim of this population study was to investigate if clinically appropriate renal function 
testing recommendations were being undertaken in New Zealand primary care for NVAF 
patients prescribed dabigatran etexilate. 
5.2.2 Methods 
5.2.2.1 Identification of Study Cohort 
This was a retrospective cohort study using administrative health data from New Zealand. 
The databases accessed were the New Zealand Ministry of Health Pharmaceutical 
Chapter five Compliance with renal function guidelines
150 
Collection  (New Zealand Ministry of Health, 2016b) (PC) and the Best Practice 
Intelligence (BPI) database operated by Best Practice Advocacy Centre Clinical 
Solutions, New Zealand. The PC contains prescription details about pharmaceutical 
dispensing claims for dabigatran etexilate along with other prescribed medicines as well 
as information on gender, date of birth, age, ethnicity, frequency, and quantity dispensed 
for all of the New Zealand population (McBain et al., 2018; Thorne et al., 2015). The 
BPI database is a secure, internet-based, reporting tool that uses data downloaded from 
the enrolled general practice patient EHR and covers about 20% of the New Zealand 
population and contains the patient health data such as diagnosis and laboratory results. 
The study population included primary care patients: with a diagnosis of AF by a general 
practitioner (READ codes G573, G5730, G5731, G5732, G573z); aged 18 years or older; 
had at least one dispensing of dabigatran etexilate during the study period between July 
1, 2011 (when dabigatran etexilate became available in New Zealand), and December 
31, 2014. The information from different datasets were linked using each patient's 
encrypted National Health Index number (NHI number; a life-long unique identifier for 
all interactions with the New Zealand health system) to ensure patient anonymity. Ethical 
approval was obtained from the University of Otago, New Zealand Ethics Committee 
(Reference: HD15/054) (See Appendix 1 & 2). 
5.2.2.2 Patient Covariates 
Dispensed medications, patient demographics, deprivation scores, and covariate data 
were extracted from the PC and BPI databases for patients who meet the inclusion criteria 
as defined above. Patients were categorised into age groupings of under 65 years, 65 to 
74 years, 75 to 79 years, and over 80 years to align to both regulatory agencies and the 
categories used by the sponsor to guide dosing (Boehringer Ingelheim (N.Z.) Limited, 




2017; Committee for Human Medicinal Products (CHMP), 2007). The treatment period 
with dabigatran etexilate was determined by the number of days supplied for each series 
of continuous treatment. Continuous dabigatran etexilate use was defined as one or more 
dispensings recorded in the PC with less than 120 days between dispensing (prescriptions 
in New Zealand for dabigatran etexilate typically supply 90 days which are dispensed in 
30-day amounts). When 120 days or more elapsed between dabigatran etexilate 
prescriptions, a patient was considered to have ceased dabigatran etexilate treatment. If 
the patient restarted dabigatran etexilate treatment after 120 days or more had elapsed, 
they were considered as a new patient in the study. 
5.2.2.3 Serum Creatinine Measurements 
Evidence reflecting measurement of renal function at any time during dabigatran 
etexilate treatment were extracted and analysed. Results of all serum creatinine tests 
reported within close proximity to the current clinical guidance were included. Close 
proximity was defined as a completed serum creatinine measurement within one month 
either side of the specified time (Graham et al., 2004; Schmidt et al., 2017). If multiple 
measurements were recorded within close proximity of the specified time, only the 
measurement closest to the testing date was utilised for the analysis. Compliance to 
recommended renal function testing protocols were examined. Compliance was defined 
as meeting the minimum recommended renal function monitoring of having a renal 
function test undertaken at treatment initiation and at 12 months post-dabigatran 
etexilate treatment initiation. Those patients who had dabigatran etexilate initiation after 
December 31, 2013 were excluded from the follow-up serum creatinine test analysis as 
this data was outside the database timeframe limits. 
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5.2.2.4 Statistical analysis 
Statistical analyses were performed using Stata/IC (Version 14.2, StataCorpLP, TX, 
USA). Continuous variables were tested for normal distribution by the skewness and 
kurtosis test. Normally distributed data are presented as the mean ± standard deviation 
and non-normally distributed data as the median (interquartile range). The proportion of 
patients who had serum creatinine measurements at close proximity to dabigatran 
etexilate treatment initiation and 12 months post-initiation were assessed with the 95% 
confidence interval (95% CI, Clopper-Pearson method) 
exact test. Additionally, the proportion of patients who had serum creatinine 
measurements at any time in the first 12 months of treatment were assessed (95% CI, 
Clopper-Pearson method) to allow for comparison with other studies (McBain et al., 
2018; Thorne et al., 2015). A box and whisker plot was utilised to investigate the 
distribution of serum creatinine tests in relation to 12 months post-treatment initiation. 
Log-rank tests for univariate analysis (gender, age, ethnicity and deprivation index score) 
based on serum creatinine testing at dabigatran etexilate treatment initiation and 12
months post were performed to investigate if there was any influence on testing. The days 
supplied of dabigatran etexilate were right-censored if a serum creatinine was not 
undertaken at treatment initiation or if a second test was not undertaken. Results were 
considered statistically significant if p < 0.05. 
5.2.3 Results 
5.2.3.1 Patient Characteristics 
There were 1,948 patients identified in the databases who had been dispensed dabigatran 
etexilate that was prescribed in the primary care setting with a diagnosis of NVAF and 
aged 18 years or more. The median age of patients in this cohort was 74 years (IQR: 67-




79.5). The median supply of dabigatran etexilate for participants was 594 days (IQR: 
190 1050 days). There were 929 (72.8% [95%CI; 70.2-75.2]) patients who received 12
months or more supply of dabigatran etexilate with treatment initiated in the time frame 
that allowed for adequate follow-up in the BPI database. A summary of the demographic 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.2.3.2 Serum Creatinine Measurements 
A total of 1,752 (89.9% [95%CI; 88.5-91.2]) patients had a serum creatinine test at close 
proximity to dabigatran etexilate treatment initiation. For those initiated on dabigatran 
etexilate a total of 868 (93.4% [95%CI; 91.6-94.9]) had undergone at least one serum 
creatinine test at any time during their following treatment. The median time to testing 
post-treatment initiation was 287 days (IQR: 208-339 days). Figure 13 shows the 
minimum, median, first quartile, third quartile, and maximum days tests were undertaken 
in relation to the closest test to 12 months post-treatment initiation (the recommended 
follow-up testing time). Of the patients who had 12 months or more supply, there were 
significantly fewer patients who had a serum creatinine test within a close proximity to 
the 12 month follow up date with a total of 207 patients (22.3% [95%CI; 19.6-25.1]) 
(p<0.0001). When investigating if these patients had undergone at least one serum 
creatinine test at any time in the first 12 months of follow-up there was a total of 823 
(88.6% [95%CI; 86.4-90.6]). For these, the median number of tests in the first 12 months 
was 2 (IQR: 1-4). Univariate analysis of demographic characteristics yielded 
insignificant log-rank tests for association with having serum creatinine measurements 
taken both at treatment initiation and at close proximity to 12 months post-initiation for 
all categories except for Pacific Peoples with none having a measurement recorded at 
12 months (Table 18).  
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Figure 13 Box plot showing median, lower and upper quartiles, and minimum and 
maximum values for the time when serum creatinine tests closest to 12 months (dashed 
line) post-dabigatran etexilate treatment initiation were undertaken (n=868) 
5.2.4 Discussion 
Our findings suggest that compliance with the recommended 12 month follow-up 
monitoring of renal function is sub-optimal for primary care NVAF patients receiving 
more than 12 months treatment of dabigatran etexilate. 
This cohort showed similar results to other New Zealand studies (McBain et al., 2018; 
Thorne et al., 2015) when the stated rules relating to renal function testing compliance 
were observed. The vast majority of patients had a serum creatinine at treatment initiation 
with most having a test at any time in the following 12 months. While this is a useful 
audit tool to encourage prescribers to actively monitor their NVAF patients, it does not 
investigate if the monitoring is being undertaken at the recommended clinically 
appropriate timeframe of 12 months. Therefore, we investigated how many of the 
patients had a serum creatinine test at treatment initiation and at 12 months. Our findings 
show that there was sub-optimal adherence to renal function testing at 12 months for 
these patients with only 22.3% [95%CI; 19.6%-25.1%] having a test recorded. 
Additionally, it has previously been reported that deprivation and inequalities lead to 




worse outcomes for those treated with dabigatran etexilate (Simpson et al., 2018b) and 
the present study also indicates that there is inequality for Pacific Peoples ( 2 =5.17; 
p=0.0230) for the follow-up renal testing. 
It is unclear why there is a large discrepancy between the proportion of patients 
undergoing renal function testing at treatment initiation compared to 12 months. One 
possibility that is highlighted in this study is that the prescribing assistant computer 
software commissioned by PHARMAC may have encouraged prescribers to assess the 
assistant did not activate for any subsequent prescriptions. During the specified time 
period of this study, no other computerised clinical decision support tools for monitoring 
renal function relating to dabigatran treatment were available for prescribers. Therefore, 
prescribers were not promp  renal function near the 
recommended 12 month time frame. Further investigation into whether clinical decision 
support can improve renal function monitoring and patient outcomes is required. Also, 
consideration is needed to ensure that any such clinical decision support initiatives should 
be designed to ensure that they meet the needs of New Zealand  diverse ethnic 
population. 
Other reasons for deviating from the recommended renal function regimen are difficult 
to isolate and can be varied. For example, clinicians maybe utilising alternative 
guidelines or following their own experiences with dabigatran etexilate. They may be 
accessing the patient at the time of prescribing and using their professional judgement to 
determine not to undertake renal function monitoring as the patient looks otherwise well, 
or possibly decided that a previous test was adequate for assessment. Also, the clinician 
may have become reliant on computerised systems providing prompts for other clinical 
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situations (Tomlin et al., 2011) and therefore inadvertently omitted requesting or 
undertaking the recommended renal function testing due to absence of an automated 
reminder. Additionally, the prescriber may have requested the test to be undertaken but 
the patient may have made the decision to not have the test done or possibly lost the 
laboratory request form. Finally, the test may have been undertaken but the results were 
not entered or entered incorrectly into the EHR. 
Undertaking routine estimation of renal function for NVAF patients is an important 
consideration during their treatment with dabigatran etexilate. Approximately 80% of 
dabigatran etexilate is eliminated via renal excretion (Ezekowitz et al., 2009) and with 
renal function decreasing significantly with age in NVAF (Simpson et al., 2018a), there 
is potential that patients can be exposed to supratherapeutic plasma levels and thus 
experience adverse drug reactions such as haemorrhage which may be life 
threatening (Simpson et al., 2019).  
The limitations of this study include that although a serum creatinine is recorded in the 
electronic health record it is not possible to ascertain if this was collected for the purpose 
of renal function estimation for dabigatran etexilate treatment. Also, the data did not 
allow for investigation into patient outcomes related to compliance to renal function 
testing. Further research is required to investigate the clinical importance of renal 
function testing compliance. The main strength of this study is the inclusion of a large 
cohort of patients with a similar demographic profile of that previously described for the 
nationwide cohort (Simpson et al., 2018b), with sufficient sample size to provide 
adequate information about renal function monitoring for an entire population. 




Improved adherence to guideline-directed stroke prevention therapy with oral 
anticoagulation drugs improves patient outcomes (Piccini et al., 2019). In New Zealand 
patients this could be achieved by the possible inclusion of a clinical decision support 
tool that provides a timely reminder prompting clinicians that renal function should be 
reassessed based on guideline specified times. If a serum creatinine measurement was 
recorded in the electronic health record the estimated renal function could be reported to 
the clinician for consideration and possible dose modifications could be investigated. 
This would be especially useful in situations where ad-hoc testing, possibly unrelated to 
dabigatran etexilate treatment, were performed and if the estimated renal function 
showed a change in renal function that warranted a dose modification then this could be 
highlighted to the prescriber for consideration outside regular review periods. 
5.2.5 Conclusion 
There appears to be sub-optimal adherence to renal function monitoring for NVAF 
patients who receive more than 12 months treatment with dabigatran etexilate in the New 
Zealand primary care setting. This may lead to incorrect dose adjustments for this 
frequently used medication and poorer outcomes for patients. Further investigation into 
whether an automated clinical decision support tool that reminds clinicians when to 
undertake renal function monitoring at clinically appropriate times can improve 
adherence to guidelines and patient outcomes is required.
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6 General Discussion
This thesis aimed to investigate aspects of dabigatran etexilate utilisation in New Zealand 
diverse population; examining how 
different estimates of renal function can influence outcomes; investigated adherence to 
recommend renal function monitoring; and explored a novel technique for therapeutic 
drug monitoring. These research objectives were developed in order to complement and 
build on the existing literature in this field, and to utilise multiple research 
methodologies. Utilisation and monitoring of outcomes for dabigatran etexilate tie 
together the four investigation chapters of this thesis. 
The first aim was to describe current use, effectiveness and safety of treatment with 
dabigatran etexilate in the New Zealand population. Until now, the effects of 
demographic factors on dabigatran etexilate treatment outcomes had not been reported 
for New Zealand patients. While previous studies have discussed the relationship 
between geographic related deprivation and poor health outcomes in general for New 
Zealanders (such as longer length of hospital stay and increased rates of hospital 
admissions), none have investigated this in relation to dabigatran etexilate 
treatment (Abas et al., 2006; Atkinson et al., 2014; Barnett et al., 2003; Exeter et al., 
2017). This study used a combination of health databases in its methodology to 
investigate if demographic factors affect patient outcomes with dabigatran etexilate. 
Patients of hnicity or who are more deprived were at greater 
risk of harm compared to the rest of the New Zealand population. This aligns with the 
findings of a New Zealand national health survey that reports 
and those living in the most deprived areas of New Zealand generally report greater 




that the time to either an adverse event or treatment failure predominately occurs in the 
first two years of treatment. With these events occurring in this timeframe, it highlights 
the importance of adhering to recommended patient monitoring at clinically appropriate 
times. For example, it is important that patients with AF, who are being treated with oral 
anticoagulation, have renal function testing at the recommended timeframes as they 
exhibit a more rapid decline in renal function over time (Böhm et al., 2015). Moreover, 
with studies indicating that patients treated with dabigatran etexilate experience varying 
levels of compliance to renal function monitoring  (Best Practice Advocacy Centre 
(bpacnz), 2017a; Thorne et al., 2015), it further highlights the importance of increasing 
the awareness of both clinicians and patients to ensure appropriate monitoring is 
undertaken. 
The second aim was to investigate the difference between different estimators of renal 
function and the risk of adverse outcomes for patients with atrial fibrillation when these 
different estimators were used for dose selection of dosing dabigatran etexilate. Previous 
studies have demonstrated, through simulations, that there would be clinically important 
risks to prescribing practice for dabigatran etexilate if alternatives to the Cockcroft-Gault 
equation (the method used in the initial clinical trials) were used to estimate renal 
function (Dowling et al., 2013; Hellden et al., 2013; Hudson et al., 2014; MacCallum et 
al., 2013). It has been previously reported that New Zealand clinicians predominately use 
eGFR reported by laboratories (Howey et al., 2013). This study demonstrated that 
substituting renal function estimated by CrCl (Cockcroft-Gault) with eGFR (CKD-EPI 
or CKD-EPI-BSA) could negatively influence adverse outcomes with dabigatran 
etexilate for some patients, with elderly patients having the highest risk. This is likely to 
be the result of higher doses of dabigatran etexilate being prescribed for patients whose 
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renal function is near the limits of the recommended dose stratifications. The greatest 
dose discordance compared to the Cockcroft-Gault equation was observed for: (1) 
patients over 75 years of age for CKD-EPI (received a supratherapeutic dose) and (2) 
patients over 80 years of age for CKD-EPI-BSA (received a supratherapeutic dose). Of 
the renal function estimator methods investigated, only high doses of dabigatran etexilate 
estimated by the Cockcroft-Gault equation showed a statistically significant increased 
hazard ratio of 2.32 (95% CI: 1.22 4.42; p=0.001) for a haemorrhage. This indicates that 
the Cockcroft-Gault equation is a better predictor of appropriate dabigatran etexilate 
dosing than the CKD-EPI and CKD-EPI-BSA equations as they do not effectively 
prevent the recommendation of inappropriately high doses of dabigatran. This can be 
attributed to those patients whose renal function is nearing the recommended dose 
stratification limits and being over estimated by the CKD-EPI and CKD-EPI-BSA 
equations. Thus, not receiving a clinically appropriate dose reduction based on renal 
function and suffering a haemorrhage. Additionally, the equations CKD-EPI and CKD-
EPI-BSA showed only fair to moderate agreement (weighted Kappa coefficients of 0.47 
and 0.71 respectively) with the Cockcroft-Gault equation for this cohort of patients. This 
indicates that the Cockcroft-Gault equation should not be substituted by the CKD-EPI 
and CKD-EPI-BSA equations for estimating renal function when determining the dose 
of dabigatran etexilate, especially in the elderly. When determining dabigatran etexilate 
dose adjustments based on renal function, clinicians should use the method utilised in the 
clinical trial pharmacokinetic studies (i.e. the Cockcroft-Gault equation). This is 
particularly pertinent in primary care as dabigatran prescribing is increasingly used in 




The third aim was to investigate the relationship between dabigatran etexilate exposure 
and adverse response in real-world patients. It has been discussed in the literature that 
dabigatran etexilate therapeutic drug monitoring could reduce major bleeds by 30-40% 
when compared with the well-controlled warfarin (Cohen, 2014). Currently there are no 
published data on clinical therapeutic reference ranges for optimum dabigatran etexilate 
treatment. This study demonstrated the feasibility of using measures of dabigatran 
etexilate pharmacokinetic exposure to optimise dosing and potentially improve patient 
outcomes. By utilising a novel approach of combining individual patient data, treatment 
outcomes and a previously developed population pharmacokinetic model of dabigatran 
etexilate the area under the curve (AUCss) for each individual patient were derived. The 
derived AUCss were divided into quartiles and adjusted incidence rate ratios (IRR) for 
outcomes were calculated. It was observed that there was a greater risk for a haemorrhage 
for those patients with an AUCss in the fourth quartile, while there was a protective effect 
observed in the second quartile. In relation to thromboembolism, where a knowledge gap 
in the literature exists (Committee for Medicinal Products for Human Use (CHMP), 
2014), there was also a protective effect observed for those patients with an AUCss in the 
third quartile. Therefore, adjusting doses to achieve an AUCss that is in the range of 1.70 
to 2.26 mg*h/L may result in better outcomes for patients.  
The fourth aim was to investigate if clinically appropriate renal function testing 
recommendations were being undertaken in New Zealand primary care for atrial 
fibrillation patients prescribed dabigatran etexilate. Undertaking routine estimation of 
renal function for NVAF patients is an important consideration during their treatment 
with dabigatran etexilate. Approximately 80% of dabigatran etexilate is eliminated via 
renal excretion (Ezekowitz et al., 2009) and with renal function decreasing significantly 
Chapter six General Discussion
168 
with age in NVAF (Simpson et al., 2018a), there is potential that patients can be exposed 
to supratherapeutic plasma levels and thus experience adverse drug reactions such as 
haemorrhage which may be life threatening (Simpson et al., 2019). Previously it has been 
shown that improved adherence to guideline-directed stroke prevention therapy with oral 
anticoagulation drugs improved patient outcomes (Piccini et al., 2019). The findings of 
this study showed that only 22.3% [95%CI; 19.6%-25.1%] of these patients had a renal 
function test recorded 12 months after treatment initiation. Additionally, there was 
inequality shown for Pacific Peoples ( 2 = 5.17; p = 0.0230) for the follow-up renal testing 
at 12 months. This may lead to incorrect dose adjustments for dabigatran etexilate and 
poorer outcomes for patients. This study suggested that compliance with the 
recommended 12 month follow-up monitoring of renal function was sub-optimal for 
primary care non-valvular atrial fibrillation (NVAF) patients receiving more than 12
months treatment of dabigatran etexilate. Further investigation into whether an 
automated clinical decision support tool that reminds clinicians when to undertake renal 
function monitoring at clinically appropriate times can improve adherence to guidelines 
is required. 
6.1 Limitations and strengths 
6.1.1 Limitations 
As with all research, the work described in this thesis has limitations. These are discussed 
in-depth in chapters two through five. Common limitations that are shared for the studies 
 NMDS (chapters 
two, three and four) only capturing patient data for those who require hospitalisation for 
a duration of more than 4 hours. Therefore, outcomes of interest that did not meet these 




example, a haemorrhage or CVA that resulted in death that did not occur in hospital 
would not appear in the NMDS. Also, there could be errors in the clinical codes entered 
in the NMDS resulting in possible inclusion or exclusion of the clinical outcomes of 
interest. The NMDS uses the ICD-9-AM clinical coding system. A similar version of 
ICD-9 (ICD-9-CM) has been reported to have high sensitivity when used to identify 
haemorrhagic events (93% sensitivity and 88% specificity to identifying a definite major 
haemorrhagic event) (Arnason et al.). Similarly, it has been reported that using ICD-10 
to identify CVA has a positive predictive value (PPV) of close to or greater than 90% 
and therefore adequate to identify CVA (Woodfield et al., 2015). It was assumed that the 
ICD-10-AM used to identify haemorrhagic events had high sensitivity and specificity 
and those used to identify CVA had a high PPV. These limitations to clinical coding 
contribute to background variability but would not be expected to contribute to a 
systematic bias. Additionally, the Pharmaceutical Collection only provides information 
relating to the dispensing of medications and it is not possible to confirm if the patients 
within this cohort have adhered to the prescribed regimen. 
5.1.1 Strengths 
Study design, whole of population, and study populations largely relative to the national 
cohort (i.e. warrants ignoring finite population correction) are key strengths of the four 
studies of differing methodology that makeup this thesis. This is highlighted firstly in 
chapter two, with the national retrospective cohort study investigating current use, 
effectiveness and safety of treatment with dabigatran etexilate in the New Zealand 
population. This study includes a national cohort of patients, providing information about 
the effects of demographics on dabigatran etexilate outcomes for an entire population. 
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investigating how different renal function estimators influences outcomes with 
dabigatran etexilate and compliance with renal function monitoring, included a large 
primary care population, relative to the national cohort, with a similar profile to that of 
th le size is sufficient to provide adequate 
information about the effects of different renal function estimators on dabigatran etexilate 
outcomes for an entire population. Finally, in chapter four, the mixed methodology of 
combining real-world pharmacovigilant data and a population pharmacokinetic model 
for dabigatran etexilate similarly included a large primary care population relative to the 
national cohort providing adequate information about dabigatran etexilate exposure 
response. 
6.2 Future directions 
Ultimately, the overall aim beyond the scope of this thesis is to use the data obtained for 
this thesis to improve patient outcomes for those treated with dabigatran etexilate. In the 
future, there are at least three separate studies planned, utilising the data obtained from 
this thesis, that will be designed to investigate if patient outcomes can be improved. The 
first study will develop an automated clinical decision support (CDS) tool for dabigatran 
etexilate and investigate if it improves patient outcomes. This CDS tool will alert 
clinicians when important monitoring and dose modifications are required for those 
treated with dabigatran etexilate. For example, it will detect and inform clinicians when 
renal function monitoring is required then estimate the renal function, via the Cockcroft-
Gault equation, and recommend dose modifications as appropriate for the clinician to 
consider. Compliance to recommended renal function monitoring protocols and patient 





development and service delivery initiatives. The aim of these initiatives will be to 
of health as non-  
The second study will investigate the economic viability of therapeutic drug monitoring 
(TDM) for dabigatran etexilate treatment. This study will aim to determine if point-of-
care dabigatran TDM is cost effective and make recommendations for future treatment 
guidelines. Finally, the third study will use PK/PD models to simulate alternate dosing 
regimens of dabigatran etexilate. This study will aim to determine if new dosing 
strategies can be developed to improve attaining target AUCss and thus better patient 
outcomes. 
6.3 Conclusion 
In conclusion, this thesis examined several aspects of dabigatran etexilate utilisation in 
New Zealand. It has provided new evidence that demographic factors can directly affect 
outcomes for those treated with dabigatran etexilate and real-world evidence for when 
these events occur. Improvement of outcomes could be achieved by increased vigilance 
of clinical monitoring especially in the the elderly 
and those who are in areas of higher deprivation. Both CKD-EPI and CKD-EPI-BSA 
equations significantly overestimated renal function in the elderly population compared 
with the Cockcroft-Gault equation. This may lead to dose selection errors for dabigatran 
etexilate, particularly for those with severe impairment, increasing the risk of an adverse 
outcome due to drug accumulation. Hence, CKD-EPI and CKD-EPI-BSA equations 
should not be substituted in place of the Cockcroft-Gault equation in older adults for the 
purpose of renal dosage adjustments. Furthermore, it was demonstrated that there is a 
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relationship between dabigatran etexilate exposure and adverse response in real-world 
patients. It was established that it is feasible to provide guidance for optimal dosing to 
improve outcomes for patients with AF. This is particularly relevant for elderly patients 
who are at greater risk of adverse treatment outcomes due to increase frailty. Finally, 
there appears to be sub-optimal adherence to renal function monitoring for NVAF 
patients. This may lead to incorrect dose adjustments and poorer outcomes for patients. 
Further investigation into whether an automated clinical decision support tool that 
reminds clinicians when to undertake renal function monitoring at clinically appropriate 
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Appendix 4  Paper 2: Choice of Renal Functions Estimator 
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Appendix 5  Paper 3: Exposure Response Supports 
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